Provide advice on life-style modifications for all people with high blood pressure (BP) and those with borderline or high-normal BP. Advice on effective nonpharmacological interventions is provided (A). Initiate antihypertensive drug therapy in people with sustained systolic BP (SBP) X160 mmHg or sustained diastolic BP (DBP) X100 mmHg (A). Make treatment decisions in people with sustained SBP between 140 and 159 mmHg and/or sustained DBP between 90 and 99 mmHg according to the presence or absence of cardiovascular disease, other target organ damage, or an estimated cardiovascular disease (CVD) risk of X20% over 10 years, according to the Joint British Societies CVD risk assessment programme/risk chart (A). CVD risk replaces CHD risk estimation to reflect the importance of stroke prevention as well as CHD prevention. The new CVD risk threshold of X20% is equivalent to a CHD risk of approximately X15% over 10 years. In people with diabetes mellitus, initiate antihypertensive drug therapy if SBP is sustained X140 mmHg and/or DBP is sustained X90 mmHg (B). In nondiabetic people with hypertension, the optimal BP treatment goals are: SBP o140 mmHg and DBP o85 mmHg. The minimum acceptable level of control (Audit Standard) recommended is o150/o90 mmHg. Despite the best practice, these levels will be difficult to achieve in some hypertensive people (B). In people with diabetes and high BP, optimal BP goals are: SBP o130 mmHg and DBP o80 mmHg. The minimum acceptable level of control (Audit Standard) recommended is o140/o80 mmHg. Despite the best practice, these levels will be difficult to achieve in some people with diabetes and hypertension (B). Meta-analyses of BP-lowering trials have confirmed that, in general, the main determinant of benefit from BP-lowering drugs is the achieved BP, rather than choice of therapy. In some circumstances, there are compelling indications and contraindications for specific classes of antihypertensive drugs, and these are specified (A). Most people with high BP will require at least two BP-lowering drugs to achieve the recommended BP goals. A treatment algorithm (AB/CD) is provided to advise on the sequencing of drugs and logical drug combinations (C). When there are no cost disadvantages, fixed drug combinations are recommended to reduce the number of medications, which may enhance adherence to treatment (C). Other drugs that reduce CVD risk must also be considered, notably, low-dose aspirin and statin therapy (A). Unless contraindicated, low-dose aspirin (75 mg/ day) is recommended for all people needing secondary prevention of ischaemic CVD, and primary prevention in people with hypertension over the age of 50 years who have a 10-year CVD risk X20% and in whom BP is controlled to the audit standard (A). Statin therapy is recommended for all people with high BP complicated by CVD, irrespective of baseline total cholesterol or low-density lipoprotein (LDL)-cholesterol levels. Similarly, statin therapy is also recommended for primary prevention in people with high BP who have a 10-year CVD risk X20%, estimated from the Joint British Societies CVD risk-assessment programme/chart. Optimal cholesterol lowering should reduce the total cholesterol by 25% or LDL-cholesterol by 30% or achieve a total cholesterol of o4.0 mmol/l or LDL-cholesterol of o2.0 mmol/l, whichever is
Introduction
These guidelines update previous reports by working parties of the British Hypertension Society (BHS) in 1989, 1 1993 2 and 1999. 3 Updating these guidelines is appropriate because, since 1999, there has been much new evidence in key areas that has allowed us to reinforce and extend previous recommendations.
Newly collated epidemiological data have strengthened the well-recognised relationship between blood pressure (BP) and cardiovascular disease (CVD) risk and have confirmed the overwhelming importance of systolic BP (SBP) as a determinant of risk. 4 The importance of BP as a risk factor was further underscored by the recent World Health Organisation (WHO) report which identified high BP as one of the most important preventable causes of premature morbidity and mortality in developed and developing countries. 5 New epidemiological data have also demonstrated the likelihood that in a majority of people high-normal BP will evolve to hypertension with ageing. 6 This observation prompted the US Joint National Committee 7 (JNC 7) report to introduce a new classification of BP; 'pre-hypertension', referring to those with high-normal BP. 7 The BHS has resisted the temptation to give such people a disease label, but acknowledge that lifestyle modification is appropriate for people with high-normal BP to reduce the likelihood of them developing 'hypertension' and the need for drug therapy.
There have also been new data on the safety and effectiveness of different classes of BP-lowering drugs, including much needed data on angiotensin-converting enzyme (ACE) inhibitors, dihydropyridine and non-dihydropyridine calcium channel blockers (CCBs) and angiotensin receptor blockers (ARBs). [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] These data have been subject to metaanalyses that have provided evidence that overall most classes of drugs are similarly safe and effective. [22] [23] [24] Moreover, these meta-analyses have confirmed that the benefits of BP-lowering therapy are primarily determined by the level of BP control rather than the class of drug used to achieve it. Another important conclusion drawn from analysis of these new trials is that prior concerns about the safety of dihydropyridine CCBs in people with hypertension 25 and/or diabetes 26 were unwarranted and are unfounded.
Additional new data included in this guideline relate to: the management of high BP in people with diabetes, especially type II diabetes; 13, 21, [26] [27] [28] [29] [30] [31] [32] the treatment of high BP among those with established cerebrovascular disease, 16 the treatment of people with target organ damage (TOD) such as left ventricular hypertrophy (LVH) 12 and chronic renal disease; [18] [19] [20] 33 and the treatment of hypertension in ethnic groups, especially in the black population. 21 There are also much new data on the effectiveness of lifestyle measures in the prevention and treatment of hypertension and diabetes. [34] [35] [36] [37] [38] [39] [40] [41] [42] This new information adds to an already formidable body of evidence confirming the effectiveness of BP lowering in reducing the risk of CVD.
The BHS remains concerned that national and international surveys continue to reveal that there is a substantial under-diagnosis, under-treatment and poor rates of BP control in the UK. 43 The situation has improved in recent years, but, in general, the management of hypertension in the UK remains suboptimal for the majority. 44 One of the key reasons for poor BP control in people with treated hypertension is the use of monotherapy by most doctors. 44 This contrasts with the evidence from clinical trials which have consistently shown that the majority of patients require two or more drugs to achieve current BP goals. Put simply, monotherapy for hypertension is usually inadequate therapy. To address this serious shortfall in treatment, the BHS has published a treatment algorithm based on the AB/CD rule. 45 This AB/CD algorithm is now formally incorporated into this guideline and underscores the need for at least two BP-lowering drugs for most people with hypertension. Moreover, it provides advice on rational drug selection and sequencing, based primarily on the age and ethnicity of the patient. Importantly, the AB/CD algorithm is not prescriptive or restrictive and offers therapeutic choice within a structured template.
The 1999 BHS guidelines 3 emphasised the fact that high BP should not be viewed as a risk factor in isolation. It is well recognised that people with hypertension frequently have a clustering of additional risk factors for CVD, including dyslipidaemia, impaired glucose tolerance, central obesity and hyperuricaemia-features of the metabolic syndrome. 46 Consequently, the treatment of BP in isolation will leave the patient at unacceptably high risk of cardiovascular complications and death, particularly from coronary heart disease (CHD) and stroke. 47 This guideline reinforces the view that the treatment of people with hypertension should not focus solely on BP but must also formally assess CVD risk and use multifactorial interventions to reduce total CVD risk. Hence, we provide detailed guidance on the assessment of CVD risk in people with hypertension and the management of associated CVD risk factors.
Statin therapy is a safe and effective therapy that reduces the risk of CHD and stroke. Many trials of statins have included patients with high BP and the relative risk reduction in people with hypertension treated with statins is similar to that observed for people without hypertension. 48 The Anglo-Scandinavian Cardiac Outcomes Trial -Lipid Lowering Arm (ASCOT-LLA) recently added to these data by confirming that statin therapy reduced the risk of CHD and stroke in people with treated hypertension even when BP was optimally controlled. 49 Moreover, this benefit was achieved in people with an average total cholesterol of only 5.5 mmol/l, a value typical of that seen in many people with hypertension. Consistent with national guidance at the time, the previous BHS guideline-recommended targeting statin therapy only at those with established CVD or at a very high risk of developing it (X40% CVD risk (equivalent to X30% CHD risk) over 10 years) and only then provided that baseline total cholesterol was 45 mmol/l. In the light of new evidence, this advice is no longer appropriate. In this new guideline, we effectively abolish the concept of a baseline cholesterol threshold for intervention with statins and reduce the risk threshold to X20% CVD risk over 10 years for primary prevention. Moreover, we adopt the lower total cholesterol and low-density lipoprotein (LDL)-cholesterol goals in keeping with the recent European Society of Hypertension/European Society of Cardiology guidelines. 50 Advice on the use of low-dose aspirin is unchanged from our previous 1999 guidelines. 3 Consistent with the 1999 guidelines, 3 we endorse the continued use of the Framingham risk function, either as a computer programme or chart, to formally estimate the absolute risk to aid treatment decisions in people with stage 1 (mild) hypertension, and for the appropriate use of statins and aspirin for primary prevention. However, we have replaced CHD risk estimates with CVD risk estimates to reflect the treatment objective: to reduce all cardiovascular events, including stroke. This is consistent with forthcoming updated Joint British Society risk charts and computer programme.
Finally, we acknowledge that guidelines achieve nothing if they are not implemented. While awareness and familiarity with BHS guidelines in the UK is generally high, their implementation is inadequate. Adherence to these guidelines is key to improving BP and CVD risk management. The majority of BP management will take place in primary care and these guidelines are intended for general practitioners (GPs), practice nurses and generalists in hospital practice. We have tried to present the best currently available evidence on hypertension management and associated CVD risk factor management as clearly as possible. We have included an extended section on implementation, audit standards and the implications of this guideline for National Service Frameworks (NSFs) and the General Medical Services (GMS) contract for primary care. We also acknowledge the importance of involving patients in treatment decisions and clinical monitoring and welcome a contribution from the Blood Pressure Association, a patients' association for people with high BP.
These guidelines have been prepared by the BHS guidelines working party on behalf of the BHS. The working party reviewed new data published since the previous guideline and updated and amended the recommendations accordingly. The document was reviewed by members of the BHS and was sent out for review by a large number of National Stakeholder organisations (Appendix A). This ensured review by personnel with a broad range of expertise across the Health Care community, including patient organisations. The evidence supporting the recommendations contained in these new BHS guidelines is graded using the North of England Group Criteria 51 (Appendix B). These guidelines should be applied with due regard to local circumstances and policies, and with appropriate clinical judgement as regards the needs of individual patients.
Blood pressure measurement

The BHS definition and classifications of BP levels have changed in line with recent European Guidelines and WHO/ISH (Box 1). 50, 52 Large variations in BP are normal in individuals. Hence, BP should be measured as accurately as possible using the BHS protocol (see Box 2) . All adults should have their BP measured routinely at least every 5 years. Those with high-normal BP (SBP 130-139 mmHg or diastolic BP (DBP) 85-89 mmHg) and those who have had high BP readings at any time previously should have their BP re-measured annually.
BP measurement can be made in the clinic, home setting or using ambulatory blood pressure monitoring (ABPM).
Clinic measurement BP should initially be measured in both arms as patients may have large differences (410 mmHg) between arms. The arm with the higher values should be used for subsequent measurements. In patients with diabetes and in the elderly, measurements should also be made after at least 2 min standing, to determine whether there is significant orthostatic hypotension.
Cuffs of the appropriate size should be used (see Box 3) such that the bladder encircles at least 80% of the upper arm and it is important that the arm is supported at heart level during recordings. Using too large a cuff results in an underestimation of BP; similarly, too small a cuff will lead to overestimation. Although a universal cuff has been recommended, 53 the BHS recommends three different bladder sizes depending on arm circumference (see Box 3). It is important when purchasing any BP monitor to ensure that appropriate cuff sizes are available.
If the auscultatory method is being used, Korotkoff phase I and phase V sounds should be taken for SBP and DBP levels, respectively. If Phase V goes to zero, Phase IV should be used. At least two measurements (1-2 min apart) should be taken on each occasion, the initial measurement should be discarded and further measurements made if there are large (410 mmHg) differences between initial readings. Timing of measurement should also be considered in relation to the time of antihypertensive treatment. Atrial fibrillation can make the measurement of BP particularly difficult due to marked beat-to-beat variability. This is a particularly important consideration when using semiautomatic or automated devices. In such patients, auscultatory measurements and multiple readings are recommended.
Home/self BP monitoring
There is an increasing use of home or self BP measurement. Some of the monitors used are inaccurate and many have not been formally validated. We strongly recommend the proper use of accurate, validated and well-maintained monitors, with an appropriate cuff size. Wrist monitors, in most instances, are not as accurate as upper arm devices and are not recommended. Measurements should be made under standardised conditions (Box 3).
The potential advantages of home monitoring include: the availability of multiple recordings throughout the waking period taken over many days, which may reduce white coat effect (see later) and misinterpretation of measurement variability. Importantly, home BP measurement also involves the patient more closely in the management of their own BP. Values from home measurements tend to be lower than clinic levels. 54 Consequently, thresholds and targets of treatment based on this technique should probably be adjusted downwards (eg by 10/ 5 mmHg), although evidence for true equivalence is lacking and will be variable. The disadvantages of this technique include reporting bias, and unsupervised alteration of medication. Newer BP monitors offer the advantages of built-in printers or internally storing all BP measurements, which can be subsequently downloaded via a telephone link to the physician. There is no uniform consensus about the frequency and timing of measurements, or about what levels should be regarded as abnormal, but patients with home BP levels of SBP o130 mmHg and DBP o85 mmHg can probably be regarded as having BP levels within the normal range. 53, 54 It has been suggested that initial assessment or the assessment of treatment effects should be for a 7-day period, with recordings performed in the morning and evening, and excluding values for the first 24 h. The average of at least these 12 readings is then taken as the home BP level. 55 The potential advantages of home BP monitoring notwithstanding, there is to date, little or no evidence of these recordings predicting CVD risk or outcomes more effectively than clinic readings.
Ambulatory monitoring ABPM is increasingly used and guidelines from the BHS and Europe on the use and interpretation of this technique in clinical practice have been published. 53, 56 Only validated well-maintained machines with appropriate cuff sizes should be used 56 (www.bhsoc.org). ABPM provides more information than either home or clinic measurements, for example, 24-h BP profile including mean daytime (usually 0700-2200 h) and night-time values, and BP variability. Like home BP measurements, there are no outcome trials based solely on ABPM values. Nevertheless, an increasing body of evidence suggests that ABPM values are a better predictor of CVD risk 57, 58 and TOD 59, 60 (for TOD definition, see Table 1 ), and is a better method of assessing treatment effects on BP. Most patients can tolerate measurements recorded at between 15-and 30-min intervals during the day, and 30-and 60-min intervals at night. ABPM thus provides multiple measurements taken over a 24-26-h period (to reduce white coat effect, the initial and last hours of measurement are sometimes ignored, though the value of doing this is unclear), and, therefore, more than 70 BP estimations can be made during a single 24-h period. Of the many measures available from 24-h ABPM, mean daytime and night-time values are usually used for assessment. As for home readings, ABPM values are usually lower than clinic measurements 61 and thresholds and targets should, therefore, be adjusted downwards (eg by 10/5 mmHg). However, we acknowledge that differences exist between the various guidelines as to what are normal and abnormal ABPM values. 50 We do not recommend the use of ABPM for all patients, but it is helpful in specific circumstances (see Box 4).
'White coat hypertension' and 'white coat' effect Anticipation of measurement usually causes BP to rise due to an alerting reaction. If sufficiently exaggerated in the clinic setting, this may result in a truly normotensive person being diagnosed as hypertensive. This is often referred to as 'white coat hypertension' or isolated clinic hypertension. The same effect can occur among treated hypertensive patients when it is referred to as the 'white coat effect'. Spuriously high BP readings may also occasionally occur outside the clinic setting, when an exaggerated alerting response accompanies the application of the BP cuff.
Thus, white coat hypertension is used to describe the phenomenon of consistently elevated clinic BP levels but normal ABPM values. Its prevalence has been reported to range from 10-30% of people with high BP, and increases with age. 62 The prevalence of white coat hypertension is highly dependent on the threshold for hypertension and is much less than 10% in those with grade 2 or 3 hypertension based In combination with a thiazide/thiazide-like diuretic.
f Beta-blockers are increasingly used to treat stable heart failure. However, beta-blockers may worsen heart failure. g Thiazide/thiazide-like diuretics may sometimes be necessary to control BP in people with a histroy of gout, ideally used in combination with allopurinol.
Guidelines for management of hypertension B Williams et al on clinic readings. White coat hypertension may be the precursor of sustained hypertension, 63 and may confer an increased CVD risk, 64 although this has not been found in all studies. 65 White coat hypertension should be considered when clinic BP is consistently elevated, or resistant to treatment in the absence of TOD.
BP-monitoring devices
The auscultatory method using the mercury sphygmomanometer has been the mainstay of clinical BP measurement for many years. However, with the anticipated withdrawal of environmental mercury for health and safety reasons, alternative measurement devices are required. Any such new device should be independently validated for its accuracy and the results published in a peer-reviewed journal. BP monitors recommended by the BHS (www.bhsoc.org and Appendix C) have been validated by protocols produced by the Association for the Advancement of Medical Instrumentation 66 and/ or the BHS; 67 or the Association for the Advancement of Medical Instrumentation 66 and/or the more recent protocol from the European Society of Hypertension. 68 The mercury sphygmomanometer (still present in many clinics) is reliable and remains the gold standard, if properly maintained and used according to strict criteria (see Box 2) . Aneroid devices are used widely, although these monitors are notoriously difficult to maintain in an accurate state over time, differ systematically from mercury devices, and are, therefore, not recommended for routine use.
Fortunately, an increasing number of well-validated, accurate and reasonably priced semi-automated devices are now available. A list of currently available monitors, validated to BHS standard, is available on the BHS Information Service website (www.bhsoc.org and Appendix C). However, many of these monitors have been developed for selfmeasurement of BP, and may not stand up to the rigours of daily clinic use, and their capacity to maintain accuracy over time is unknown.
ABPM devices remain relatively expensive and vary considerably in their accuracy, size, weight and noise level, as well as ease of use and information provided by the accompanying software. Currently available and validated ABPM devices can also be found on the BHS Information service website (www.bhsoc.org and Appendix C). Note that chest X-ray, urine microscopy and culture and echocardiography are not required routinely. An echocardiogram is valuable to confirm or refute the presence of LVH when the ECG shows 'high' left-ventricular voltage without T-wave abnormalities, as is often the case in young patients. When the clinical evaluation or results of these simple investigations suggest a need for further investigation, it may be best to refer for specialist advice, if the additional investigations needed are difficult to arrange from general practice. Indications for referral for specialist advice or treatment are suggested in Table 3 . Intuitive estimates of risk are crude and inaccurate. 70 Some guidelines have stratified risk based on the number of risk factors, the presence or absence of TOD and the presence of associated clinical conditions such as diabetes or renal disease. 52, 71, 72 The BHS believes that risk estimation is more accurate when major risk factors are evaluated and weighted using risk functions derived from epidemiological studies. The most commonly used is the Framingham risk function, 73 which has been shown to apply to Northern European populations including Britain. 74 One recent report suggests that the Framingham algorithm exaggerates CHD risk in the UK context. 75 This study, which was confined to men aged 40-59 years and which did not examine stroke risk, was none the less interesting because it suggested that it may in future be possible to adjust the Framingham equations to apply more accurately to the British population. More prospective data relating to CHD and stroke in British men and women will be required. In the same study, 75 using the thresholds of 415% CHD risk (equivalent to 420% CVD risk) over 10 years, the Framingham equation identifies 75% of those destined to have a CHD event and any overestimation of CHD risk was less apparent. In addition, it is likely that many of the people identified at 415% CHD risk by their risk factors, who do not then experience a CVD event in the next 10 years, will do so subsequently. The effect of changing from our earlier recommendations of X15% 10-year CHD risk to X20% 10-year CVD risk for the treatment of mild hypertension and for statin therapy will be to improve the identification of people who can benefit from such treatment although its full effect on sensitivity and specificity remains to be determined. For the present, we have chosen to continue to base risk prediction on the Framingham equation, because it remains the only method of estimating the risk of cardiovascular morbidity and mortality in both men and women, which includes most of the risk factors routinely available to the clinician.
Patient evaluation/thresholds/targets
In the 1999 guidelines, 3 the BHS endorsed the use of the Joint British Societies computer programme (the Cardiac Risk Assessor) and a CHD risk chart, 76 both of which were based on the Framingham risk function. 73 These were shown to be more userfriendly than other similar risk-assessment tools.
Uptake of both the Joint British Societies chart and risk assessor was consequently very encouraging. However, the chart has two important inherent problems, in common with the others of its kind. Firstly, it predicts the 10-year absolute risk. This results in a propensity to undertreat young people at high relative risk and to overtreat older people at lower relative risk. For example, a 35-year-old woman, even if diabetic, a smoker, with a total cholesterol:HDL ratio of 9, and an SBP of 180 mmHg, does not reach the 10-year 30% risk of CHD threshold, the level at which intervention was previously recommended for some interventions. 3 In contrast, most elderly men would have qualified for intervention simply on account of their age and sex.
The second important problem of the first Joint British Societies prediction charts was the focus on CHD rather than CVD risk. In clinical practice, both the prescribing doctor and the patient are likely to be interested in all major cardiovascular events including stroke, rather than just fatal and nonfatal CHD, and certainly not just fatal events which a recent European approach has favoured. 77 In light of these two shortcomings, the latest Joint British Societies chart has been modified so that anyone below age 50 years will be assessed on the basis of their risk factors as if they were aged 49 years and all those aged 60 years and above will be assessed as if they were 69 years of age. This helps to improve the balance of emphasis between relative and short-term absolute risk. The chart now predicts 10-year CVD risk (combined fatal and nonfatal stroke and CHD) and, in view of the changing thresholds for intervention with statins (see later section), the only threshold emphasised in the charts is 20% 10-year CVD risk.
A further major change in the Joint British Societies risk charts is the lack of a separate chart for people with diabetes. This is based on the belief that the need for risk estimation among people with diabetes is rarely, if ever, required. The most recent Adult Treatment Program III (ATPIII) report 46 recommended that those with type II diabetes should be considered as 'coronary equivalents' (ie having the same CVD risk as a person who has established CHD), that is, 'secondary prevention', thereby obviating the need for formal risk assessment. This is based on one Finnish study 78 which conflicts with other epidemiological data. 79 However, the best current evidence strongly suggests that the CHD risk among people with diabetes aged 450 years, or those who have been diagnosed for at least 10 years, is equivalent to that to which those who have suffered a myocardial infarction (MI) are exposed. Furthermore, the short-and long-term case fatality rates following an MI among patients with diabetes are much higher than for those without. Hence for simplicity, given that most patients with type II diabetes are aged 450 years, it seems reasonable to treat all patients with diabetes as 'coronary equiva-lents', thereby removing the need for total (often confusingly referred to as global) risk estimation. A risk scoring system ('engine') has been developed, based on the UK Prospective Diabetes Study (UKPDS), and this could be used for all patients with diabetes (including those with type I diabetes). 80 While this is undoubtedly the most accurate tool for assessing risk in people with diabetes, the threshold for intervention is exceeded by the substantial majority of these patients. There is a lack of evidence of the levels of cardiovascular risk and thresholds for intervention in patients with type I diabetes. Pending further evidence, it is reasonable to treat 'older' (440 years) patients as type II diabetes, and to formally calculate the risk of younger type I diabetic patients using one of the dedicated risk assessors (Joint British Societies and the UKPDS risk engine), although these calculate risk for patients with type II diabetes.
The inadequacies of any risk-assessment system are acknowledged. 75 Nevertheless, the assessment of total risk is increasingly endorsed and encouraged as a guide to clinical practice, and strategies which do not incorporate such an approach are likely to be less cost-effective.
Improving accuracy at the expense of simplicity can only be realised by computerised systems, which incorporate many more variables, many of which are not routinely recorded. Moreover, the ideal system should predict major fatal and nonfatal cardiovascular (rather than coronary) events and incorporate some method of avoiding the shortcomings of predicting only short-term absolute risk. Despite more emphasis on simplicity than accuracy, the charts produced in these guidelines are the best available option. This tool, like all of the others available, should be used to guide rather than rule practice by clinicians who should be fully aware of the shortcomings of the system in use.
Blood pressure treatment thresholds (Box 5)
Previous BHS guidelines 2,3 advised early drug treatment of patients with more severe hypertension (X200/110 mmHg) and treatment of sustained BP X160/100 mmHg. These recommendations remain sound and are not altered. It is recommended that all patients with grade I hypertension SBP: [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] and/or DBP: 90-99 mmHg) should be offered antihypertensive drug treatment if: (i) there is any complication of hypertension or TOD (for TOD definition see Table 1 ), or diabetes (Table 1 ) and/or (ii) the estimated 10-year CVD risk is X20%, despite lifestyle advice.
Decisions on treatment at lower levels of CVD risk may also be influenced by the patient's attitude to treatment, and the benefit anticipated from treatment.
When a decision not to treat any patient with grade I (mild) hypertension is made, it is essential to continue observation and monitoring of BP, at least annually. BP will rise within 5 years to levels clearly requiring treatment in about 10-15% of patients. In addition, CVD risk will increase with age, and therefore risk should be reassessed accordingly. These patients should all be encouraged to continue with lifestyle measures to lower BP and CVD risk.
Thresholds for intervention are summarised below and in Figure 1 . (Figure 2 , see Appendix D for instructions on how to use the charts); treat if the estimated 10-year CVD risk is X20%.
BP treatment targets
Randomised controlled trial evidence on optimal targets for BP lowering is incomplete, with better evidence for DBP targets 81 than SBP targets, although for most patients above age 50 years, SBP is clearly a more important prognostic determinant of adverse CVD outcome. 82 From all the intervention trials in hypertensive people, including those with and without diabetes, those at high CVD risk and those post stroke, the overwhelming evidence for an optimal DBP supports a 'lower the better' policy, 24 without any convincing evidence of a J-curve relationship. Despite limitations, the Hypertension Optimal Treatment (HOT) trial provides the best evidence to date on optimal targets during antihypertensive treatment of patients with a DBP of 100-115 mmHg. 81 Using an analysis based on achieved BP levels rather than an intention-to-treat approach, optimal target BP was reported to be 139/83 mmHg and reduction of BP below the optimal level caused no harm. Importantly, patients were little disadvantaged in the HOT trial provided BP was reduced below 150/90 mmHg. In light of these observations, in the 1999 BHS guidelines, we recommended a BP target of o150/90 mmHg as an 'Audit standard', that is, the minimum target which all treated patients should attain. This recommendation remains unchanged.
In the HOT trial, an important practical finding was that the optimal DBP was attained by titrating treatment in a stepped-care fashion, aiming for DBP targets of either p90, p85 or p80 mmHg. With this systematic method of treatment, the final DBP was above 90 mmHg in only 7% of patients.
For decades physicians have based their treatment on DBP targets. With increasing recognition of the importance of SBP as a risk predictor, several trials both completed and in progress, aim for both SBP and DBP targets of o140/90 mmHg. SBP targets are usually more difficult to achieve than DBP targets, but with adherence to a structured treatment algorithm, including dose titration of drugs and recommendations for add-on therapy, SBP targets of 140 mmHg can be achieved in the majority of patients. 49, 83 Among people with hypertension and diabetes in the HOT trial, there appeared to be a significant advantage, using an intention-to-treat analysis, of aiming for a DBP pressure p80 mmHg, which halved the incidence of major cardiovascular events compared with treatment aiming for a DBP p90 mmHg. 
Lifestyle advice
Lifestyle measures
Lifestyle measures for BP reduction are given in Box 7 and Table 4 .
Primary prevention of hypertension
Current approaches to the prevention of adverse cardiovascular sequelae due to hypertension are unsatisfactory since they require prolonged drug therapy for a large proportion of the adult population. Moreover, this strategy does not reduce the risk of treated hypertensive patients to that of the normotensive population. 47 A population strategy is therefore necessary: (1) to prevent the rise in BP with age, and therefore reduce the prevalence of hypertension, (2) to reduce the need for antihypertensive drug therapy and (3) to reduce CVD burden. The BHS proposes the following lifestyle modifications for the primary prevention of hypertension consistent with those recently outlined by the US National High BP Education Program: 84 maintain normal body weight for adults (eg body mass index 20-25 kg/m 2 ); reduce dietary sodium intake to o100 mmol/ day (o6 g of sodium chloride or o2.4 g of sodium per day); engage in regular aerobic physical activity such as brisk walking (X30 min per day, most days of the week); limit alcohol consumption to no more than 3 units/day in men and no more than 2 units/ day in women. Guidelines for management of hypertension B Williams et al consume a diet rich in fruit and vegetables (eg at least five portions per day); consume a diet with reduced content of saturated and total fat.
Lifestyle changes in established hypertension
Recent controlled trials [34] [35] [36] [37] [38] 42, [85] [86] [87] [88] [89] [90] (clinical trials and trials included in reviews) have confirmed that lifestyle changes can lower BP (Table 4) . These studies were not designed to quantify changes in deaths or cardiovascular events, but rely on the surrogate end point of reduced BP and its epidemiological link to reduced CVD, and it is therefore assumed that they will reduce CVD risk.
Clear verbal and written advice on lifestyle measures should be provided for all hypertensive patients and also those with high-normal BP or a strong family history. Effective lifestyle modification may lower BP as much as a single BP-lowering drug. 34 Combinations of two or more lifestyle modifications can achieve even better results. 34 Lifestyle interventions reduce the need for drug therapy, can enhance the antihypertensive effects of drugs, reduce the need for multiple drug regimens and can favourably influence overall CVD risk. Conversely, failure to adopt these measures may Audit standard reflects the minimum recommended levels of BP control. Despite best practice, the Audit Standard will not be achievable in all treated hypertensives. For ambulatory (mean daytime) or home BP monitoring, reducing these targets by B10/5 is recommended. BP ¼ blood pressure; SBP ¼ systolic blood pressure; DBP ¼ diastolic blood pressure.
Guidelines for management of hypertension B Williams et al
attenuate the response to antihypertensive drugs. Lifestyle measures that lower BP and may reduce CVD risk in established hypertension are outlined in Table 4 and Box 8.
In patients with grade 1 (mild) hypertension, but no cardiovascular complications or TOD, the response to these measures should be observed during the first 4-6-month period of evaluation. When drug therapy has to be introduced more urgently, for example, in patients with grade 3 (severe) hypertension, lifestyle measures should be instituted alongside drug treatment. The initiation of drug treatment should never be delayed unnecessarily, especially in patients at higher levels of risk.
Weight reduction by calorie restriction is appropriate for the majority of hypertensive patients because most are overweight. 91 Low-calorie diets have a modest effect on BP in such individuals, [92] [93] [94] but nearly 50% can expect a reduction of 5/5 mmHg or better in the short term. Body mass index is frequently used as a measure of overweight but other measures of obesity, particularly central obesity, are better markers of adverse cardiovascular outcomes. 95 Weight reduction also has beneficial effects on associated risk factors such as insulin resistance, diabetes, dyslipidaemia and LVH. 96 The BP-lowering effect of weight reduction 97 may be enhanced by a simultaneous increase in physical exercise, 98 by alcohol moderation in heavy drinkers 99 and by reduction in sodium intake. 100 Salt reduction from an average of 10 to 5 g (5 g ¼ B1 teaspoon) daily lowers BP by about 5/2 mmHg 100-105 with larger BP falls in the elderly and in those with higher initial BP levels. 106 About one-third of people will achieve a reduction of 5/ 5 mmHg or more. These effects are additive to the BP-lowering effect of a healthy diet, for example, the Dietary Approaches to Stop Hypertension (DASH) diet. 34 All hypertensive patients should have clear verbal and written advice to reduce salt intake to
Box 7 Lifestyle measures
K
Lifestyle measures: weight reduction (A), reduced salt intake (A), limited alcohol consumption (A), aerobic exercise (A), reduced total fat and saturated fat intake (A) and increased fruit and vegetable consumption (A) are effective in lowering blood pressure K Alone or in combination these interventions can reduce the need for drug therapy and enhance the effect of antihypertensive agents (A). A favourable effect on cardiovascular outcome is assumed, but not proven K To reduce the overall cardiovascular disease risk, patients should stop smoking (B), reduce total fat and saturated fat intake and increase consumption of mono-unsaturated fats and oily fish (B) o6 g/day (o100 mmol/day). Many will already have discontinued adding salt at the table and, even when cooking, but few are aware of the large amount of salt in processed foods, such as bread (one slice contains 0.5 g of salt), some breakfast cereals, readyprepared meals and flavour enhancers such as stock cubes or manufactured sauces. Patients, and those who cook for patients, should be provided with specific written advice (see Appendix E-Blood Pressure Association). Alcohol intake above 21 units/week is associated with BP elevation [107] [108] [109] that is reversible by reducing the intake. 99, 110 Binge drinking is associated with an increased risk of stroke. 111 Hypertensive patients should be advised to limit their alcohol intake to 21 units/week (men) and 14 units/week (women). Structured interventions to reduce alcohol consumption have on average a small effect on BP, reducing SBP (and possibly DBP) by about 2-3 mmHg. 99, 110 Consumption of smaller amounts of alcohol, up to the recommended limit, may protect against CHD 108 and should not be discouraged. Physical activity should be regular, aerobic (eg brisk walking) and tailored to the individual patient. For example, three vigorous training sessions per week may be appropriate for fit younger patients or brisk walking for 20 minutes/day in older patients. [112] [113] [114] Isometric exercise such as heavy weight lifting is not recommended for hypertensive patients due to the associated pressor effects on BP. Taking regular aerobic exercise has a small effect on BP, reducing SBP and DBP by about 2-3 mmHg. [115] [116] [117] [118] Interventions which actively combine exercise and diet may reduce both SBP and DBP by 5-6 mmHg. [115] [116] [117] [118] 119 For patients with severe hypertension, or if hypertension is poorly controlled, heavy physical exercise should be discouraged and postponed until appropriate drug therapy has been instituted and found to be effective.
In observational studies, physical exercise appears to exert a strong protective effect against cardiovascular mortality.
120 Physical activity, either at work or in leisure time, is associated with a lower risk of CHD in men and women. [121] [122] [123] [124] The largest reduction in risk is between sedentary and moderately active individuals with a more modest reduction between moderate and vigorous activity. Protection is lost when exercise is discontinued. Any activity appears to be of benefit but those that are more active appear to gain more protection. A reasonable strategy is regular aerobic exercise (eg brisk walking) for at least 30 min, ideally on most days but at least 3 days/week.
Increased fruit and vegetable consumption is supported by controlled-trial evidence that an increase from two to seven portions daily lowers BP by around 7/3 mmHg in hypertensive patients. 125 Hypertensive patients should be given clear advice to increase fruit and vegetable intake to at least five portions per day. When this is combined with an increase in low-fat dairy products and reduction of total and saturated fat, BP falls may be larger, averaging 11/6 mmHg in hypertensive patients. 125 The mechanism whereby fruit and vegetable consumption are thought to lower blood pressure is uncertain. However, this may be due to an associated increase in potassium intake, which is compatible with some supplementation studies. 126 Lifestyle modifications NOT recommended for reducing BP: The best available evidence does not support the use of calcium, magnesium or potassium supplementation (ie tablets) individually or in combination to achieve a worthwhile reduction in BP. 39, 40, [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] Structured interventions to reduce stress (stress management, meditation, yoga, cognitive therapies, breathing exercises and biofeedback) have been shown to result in short term reductions in BP [137] [138] [139] [140] [141] but the interventions studied have been so varied, it is difficult to be prescriptive with regard to an effective strategy. Limited and inadequate evidence are available to support the use of garlic, herbal and other complimentary medicines to lower BP.
Cigarette smoking does not, except when chronic and heavy, appear to be associated with hypertension 142, 143 but BP does rise acutely during smoking, and this results in the systematic underestimation of usual BP among regular smokers, since this is usually based on clinical readings when the patient is not smoking. Extensive observational data show that smoking has a graded adverse effect on risk of cardiovascular complications 144 and increases CVD risk more than mild hypertension. It is a major factor related to the persistent increase in coronary and stroke mortality in men with treated hypertension. 47 Those who stop smoking experience a rapid decline in risk, by as much as 50% after 1 year, but up to 10 years may be needed to reach the risk level of those who have never smoked. [145] [146] [147] [148] Hypertensive patients who smoke should be given advice and help to stop smoking. Physician advice and encouragement given repeatedly over time has been shown to reduce smoking by 21%. 149 The use of nicotinereplacement therapies is safe in hypertensives and approximately doubles smoking-cessation rates. 150 All forms of nicotine replacement therapy are effective particularly in those who seek help in stopping smoking. 149, 151 Individuals need to recognise their increased risk due to smoking and also recognise the need to stop and be motivated to do so.
Dietary fat is a major determinant of the level of serum cholesterol, which with or without hypertension is an important predictor of CVD. 47 All patients should be advised to keep total dietary intake of fat to p35% of total energy intake, to keep the intake of saturated fats to p33% of total fat intake, to keep the intake of cholesterol to o300 mg per day, and to replace saturated fats by an increased intake of mono-unsaturated fats. These dietary changes can be very effective, but in clinical practice have been shown to reduce serum cholesterol by only about 6% on average, 152 because it is difficult to imple-ment and sustain such measures. 153 Regular intake of fish and other sources of omega 3 fatty acids (at least two servings of fish per week) will further improve lipid profiles and has been shown to reduce BP, 154 as does the DASH diet. 125 Effective implementation of these lifestyle measures requires enthusiasm, knowledge, patience and considerable time spent with patients and other family members. It is best undertaken by welltrained health professionals, for example, practice or clinic nurses, and should be supported by clear written information (see Appendix E-Blood Pressure Association). A common approach in successful lifestyle modification programmes is the use of group working. Healthcare teams and patient organisations could usefully provide information or organise local groups which promote healthy lifestyle changes.
Drug treatment
Introduction to drug treatment
Several classes of drugs have been used to lower BP, including thiazide/thiazide-like diuretics, beta-receptor-blocking drugs (beta-blockers), CCBs, ACE inhibitors, ARBs, alpha-adrenoceptor blockers (alpha-blockers) and older agents whose actions in general were sympatholytic, that is, they interfered at various sites with the activation of the sympathetic nervous system.
In unselected hypertensive populations, no one class of agents is any more effective at lowering BP than another. Overall, single drug therapy will reduce BP by, on average, no more than about 7-8%; however, there is substantial interindividual variation in response to single drugs with large absolute falls in some patients, contrasting with little or no response in others. 155 These large variations in drug responses reflect marked heterogeneity in the pathogenesis of BP elevations in hypertension and the multiplicity of pathophysiological mechanisms responsible for higher levels of BP. 156 There have been several attempts to profile subjects with regard to hypertensive phenotype in the hope that this would permit better selection for individual drug therapy. With one or two notable exceptions (age and ethnicity), this has been largely unsuccessful. 157, 158 The major drug classes are described below (for further reading see Kaplan 159 and Swales 160 ):
Thiazide/thiazide-like diuretics Thiazide/thiazide-like diuretics lower BP by a complex series of mechanisms. Urinary loss of sodium resulting from a blockade of renal tubular reabsorption of sodium is integral to the antihypertensive effect. Sustained actions of thiazide/thiazide-like diuretics on the kidney make them preferable to loop diuretics, with which short-term sodium and water loss may be compensated for by sodium retention during the latter part of the dosing interval and amelioration of their BP-lowering efficacy. Early blood volume loss with thiazide/ thiazide-like diuretics may be accompanied by reflex activation of several vasoconstrictor mechanisms including the renin-angiotensin-aldosterone system, which may transiently raise peripheral vascular resistance and attenuate BP lowering. The lowering of BP following the introduction of thiazide/thiazide-like diuretic therapy over a period of days, results from gradual reduction in peripheral resistance.
Thiazide diuretics (bendroflumethiazide, hydrochlorthiazide) differ from thiazide-like diuretics (chlortalidone, indapamide) in several of their actions including ion channel-blocking activity, duration of action and carbonic anhydrase inhibitory activity, the implications of which are uncertain.
Thiazide/thiazide-like diuretic use in hypertension may be associated with hypokalaemia (drug and dose dependent), impaired glucose tolerance (worse when combined with a beta-blocker), small increments in blood levels of LDL cholesterol, triglycerides and urate.
Thiazide/thiazide-like diuretic use is associated in some patients with erectile dysfunction. Their efficacy is reduced in those receiving nonsteroidal anti-inflammatory drugs (NSAIDS), and they should usually be avoided in patients with a history of gout and those receiving lithium due to a high risk of lithium toxicity.
Potassium-retaining diuretics (eg amiloride, triamterene, spironolactone) Potassium-retaining diuretics have two main roles in the treatment of hypertension. Firstly they may be used to limit potassium loss in patients treated with thiazide/thiazide-like diuretics. Secondly, spironolactone may play an important role in BP lowering in the increasingly recognised number of patients with 'resistant' hypertension in whom BP may be dependent on hyperaldosteronism. 161 These potassium-retaining diuretics act by blocking sodium/potassium exchange in the renal distal tubules. They should not be used as first-line diuretic agents, except when the diagnosis of hyperaldosteronism has been made, but rather as add-on therapy to thiazide/thiazide-like diuretics. Care is needed in patients with impaired renal function due to the risk of hyperkalaemia. Also, when combined with an ACE inhibitor or an ARB, the risk of hyperkalaemia may be increased. One side effect of the aldosterone antagonist spironolactone, that is, gynaecomastia, is common due to their antiandrogen effects.
Loop diuretics have no place in the routine management of hypertension, except in patients with impaired renal function and/or heart failure.
Beta-adrenoceptor-blocking drugs (beta-blockers)
Beta-blockers were originally developed for their antianginal properties and were subsequently found to lower BP. Despite extensive investigations, their mode of action in lowering BP remains controversial and may differ according to the individual pharmacological and physico-chemical properties of drugs within the class. Most beta-blockers, with the exception of those with strong intrinsic sympathomimetic activity, reduce cardiac output by virtue of their negative chronotropic and inotropic effects. As with diuretics, short-term haemodynamic responses are offset by reflex activation of vasoconstrictor mechanisms, which may limit initial BP lowering. Longer term reduction in arterial pressure over days occurs due to restoration of vascular resistance to pretreatment levels. Partial blockade of renin release from the kidney may contribute to the later haemodynamic response.
Beta-blockers differ in their duration of action, their selectivity for beta-1 receptors, lipophilicity and partial agonist activity. Side effects include lethargy, aches in the limbs on exercise, impaired concentration and memory, erectile dysfunction, vivid dreams and exacerbation of symptoms of peripheral vascular disease and Raynaud's syndrome. They are contraindicated in asthma and cause adverse metabolic effects, including impairment of blood glucose control and worsening of dyslipidaemia-notably reduced HDL-cholesterol and raised triglycerides. There is accumulating evidence that beta-blockers increase the likelihood of new-onset diabetes, particularly when combined with thiazide/thiazide-like diuretics.
Calcium channel blockers (CCBs)
CCBs are used for their antianginal and antihypertensive properties. The dihydropyridine CCBs (eg nifedipine, amlodipine) are more selective at blocking L-type calcium channels in vascular smooth muscle cells and thereby inducing vascular relaxation with a fall in vascular resistance and arterial pressure. Nondihydropyridine CCBs (diltiazem and verapamil) at therapeutic doses block calcium channels in cardiac myocytes, thereby reducing cardiac output. Verapamil has an additional antiarrhythmic action through its effects on the atrioventricular node.
The earlier formulations of some dihydropyridines such as capsular nifedipine have a rapid onset of action, unpredictable effects on BP, and are accompanied by reflex sympathetic stimulation, tachycardia and activation of the renin-angiotensin-aldosterone system. In some cases, they can precipitate angina. These agents have no place in the management of hypertension even in the emergency setting. Longer acting dihydropyridines have been shown to lower BP very effectively by causing arterial vasodilatation with little or no neurohumoral activation.
Side effects of dihydropyridine CCBs include dose-dependent peripheral oedema, which is not due to fluid retention, but results from transudation of fluid from the vascular compartments into the dependent tissues due to precapillary arteriolar dilatation. Gum hypertrophy occurs, but is rarely seen with nondihydropyridine CCBs. Nondihydropyridine CCBs cause less peripheral oedema, but are negatively inotropic and negatively chronotropic, and should therefore be avoided in patients with compromised left ventricular function and used with extreme caution in combination with betablockers. Verapamil use is commonly accompanied by constipation.
Angiotensin-converting enzyme (ACE) inhibitors
These drugs block the conversion of angiotensin I to angiotensin II by inhibiting ACE. The resulting reduction in levels of angiotensin II leads to vasodilatation and a fall in BP. Angiotensin II has many additional actions that are potentially harmful to the cardiovascular system and has been implicated in the pathogenesis of structural changes in the heart, blood vessels and kidneys in hypertension and in other CVD. 162 Acute falls in BP following the introduction of ACE inhibitors may occur when the renin-angiotensin system is activated, for example, in patients who are dehydrated, in heart failure, or in patients with accelerated hypertension. It is rarely seen, however, when therapy is initiated in uncomplicated hypertensive patients. Other physiological systems upon which angiotensin II may exert an important influence may contribute to the BP fall when the biosynthetic pathway is blocked by ACE inhibitors.
Side effects include the development of a persistent dry cough in 10-20% of users, 163 and rarely (circa 1%) angio-oedema. The latter is much more common in the black population (circa 4%). These drugs should be avoided in women of child-bearing potential because of the danger of foetal renal maldevelopment. They should not be used in patients with bilateral renal artery disease because they may precipitate deterioration in renal function and renal failure.
Angiotensin receptor blockers (ARBs)
These drugs block type I angiotensin II (AT1) receptors leading to vasodilatation and a fall in BP. In common with ACE inhibitors, they interfere with the actions of angiotensin II on the kidney. Owing to their receptor selectivity for the angiotensin receptor (AT1), and their lack of potentiation of bradykinin and possibly other vasoactive peptides, cough and angio-oedema are much less likely to occur than with ACE inhibitors. They are generally very well tolerated by patients intolerant of other therapies. Cautions and contraindications are similar to those outlined for ACE inhibitors.
Alpha-adrenoceptor blocking drugs (alpha blockers)
Early members of this class (eg prazosin) were shortacting drugs that blocked the activation of alpha-1 adrenoceptors in the vasculature, leading to vasodilatation. Postural hypotension was a recognised problem. Longer acting agents, for example, doxazosin and terazosin, lessen this problem. Additional properties include alleviation of some of the symptoms of benign prostatic hypertrophy. Stress incontinence may be exacerbated in women.
Sympatholytic agents and older drugs
Many of the earliest agents developed for BP control blocked the activation of the sympathetic nervous system at various levels including the cardiovascular regulatory nuclei in the brain stem, the peripheral autonomic ganglia and the postganglionic sympathetic neurone.
With one or two exceptions, few of these agents have any residual role to play in today's treatment of hypertension because side effects are common, often unpleasant and potentially harmful.
The use of methyldopa, which reduces sympathetic outflow from the brain stem will be discussed in more detail in relation to hypertension in pregnancy, which is its main indication. Other centrally acting sympatholytics include clonidine (now rarely used owing to its short duration of action and risks of withdrawal hypertension) and moxonidine a better tolerated drug, which acts as a central imidazoline receptor agonist, thereby reducing peripheral sympathetic activity.
Other vasodilators
Hydralazine-a short-acting nonselective vasodilator-has been replaced by better tolerated and more effective drugs. Minoxidil is a powerful vasodilator, the use of which is restricted to extreme resistant hypertension. It is potentially diabetogenic and stimulates body hair growth.
Intravenous nitrates, sodium nitroprusside and other intravenously administrated potent vasodilators such as fenoldopam, a dopamine agonist, are reserved for hospital use in hypertensive emergencies.
Importance of BP control
It is emphasised that optimal cardiovascular outcome is more consistently linked with BP control rather than with the drug class used to achieve it. 24 Although the evidence base on optimal target pressures for both SBP and DBP remains incomplete, in clinical practice, the majority of hypertensive patients on treatment remain well above currently recommended treatment targets for BP control. 44 Several individual trials and recent metaanalyses have shown beyond reasonable doubt that the lower the pressure the better, and that this should be the primary objective of any treatment strategy. 24 
Choice of antihypertensive drug
For each major class of antihypertensive drug, there are compelling indications for use in specific patient groups, and also compelling contraindications. There are also indications, contraindications and cautions that are less clear-cut, and which are given different weight by different doctors. These indications, contraindications and cautions for each of the drug classes are summarised in Table 2 . When none of the special considerations listed in Table 2 apply, initial drug selection should follow step 1 of the AB/ CD algorithm (see later).
Placebo-controlled trial evidence on 'older' BP-lowering drugs
Randomised placebo-controlled trials usually using diuretics and/or beta-blockers have shown significant reductions in stroke incidence of about 38%, coronary events of 16% and cardiovascular mortality of 21%. 164 The reduction in coronary events in these trials was less than the 20-25% risk reduction predicted from observational studies for a similar difference in BP. 165 The reduction in coronary events in two placebo-controlled trials using lower dose diuretics was larger at 28% than in earlier trials using higher doses of thiazide/thiazide-like diuretics. 166, 167 These lower-dose thiazide/thiazide-like diuretic-based regimens also reduced cardiovascular and all-cause mortality significantly.
The larger benefit on coronary events observed in these trials with lower-dose thiazide/thiazide-like diuretics may be related to the different populations studied (older age, higher CVD risk or predominance of isolated systolic hypertension (ISH)), to the lower incidence of hypokalaemia, or to the play of chance.
The optimal dose of thiazide/thiazide-like diuretics is unclear, but higher doses, that is, 425 mg hydrochlorthiazide or 45 mg bendroflumethiazide, or 425 mg chlortalidone, should be avoided because such doses will further increase the risk of metabolic abnormalities with little if any additional BP lowering. Whether the very low doses commonly advocated (ie hydrochlorthiazide 12.5 mg, bendroflumethiazide 2.5 mg) are the most effective doses for BP lowering or preventing cardiovascular events remains uncertain 168 and requires further study.
Placebo-controlled trial evidence on 'newer' BP-lowering drugs
At the time of the last BHS guidelines, there was little evidence from randomised controlled trials on which to base recommendations regarding the effectiveness of newer agents such as ACE inhibitors and CCBs with regard to CVD prevention. Since then, several placebo-controlled trials of ACE inhibitors have been performed, albeit not specifically in hypertensive populations. The Heart Outcomes Prevention Evaluation (HOPE), 30 Perindopril Protection Against Recurrent Stroke Study (PROGRESS), 16 EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) 17 and other trials have been carried out in patients at high CVD risk rather than high BP. In each of these trials, there were substantial reductions in CVD events in those allocated to an ACE inhibitor, accompanied by reductions in BP. It is the Committee's view that these cardiovascular benefits were most likely explained by better BP control in those allocated to the ACE inhibitor, but it is not possible to rule out other additional benefits. A single placebo-controlled trial with the dihydropyridine nitrendipine in patients with ISH resulted in convincing evidence of a reduction in CVD events in the active treatment group. 169 Study on Cognition and Prognosis in the Elderly (SCOPE) recruited mostly patients with ISH, and set out to compare the ARB, candesartan with placebo. 170 The findings were confounded by the use of BP-lowering drugs in the placebo limb, such that the BP difference between limbs was less than expected and thus the study was underpowered. There were no significant differences in the primary outcome of combined CVD events or in stroke, but the nonsignificant reductions in both these end points were similar in size to those observed in the LIFE trial.
Active comparator trials comparing different BP-lowering drugs
Little, if any, differences in combined cardiovascular outcomes were observed in a series of trials comparing older regimes (usually diuretic/betablocker based) with newer regimens based on ACE inhibitors or CCBs (CAPtopril Prevention Project (CAPPP), 10 Nordic DlLiazem study (NORDIL), 9 International nifedipine once-daily study (IN-SIGHT), 8 Swedish Trial in Old Patients with hypertension 2 (STOP2). 11 This may have been the result of the inadequate power of each of these studies to show cause-specific differences in outcome. More recently, antihypertension and lipidlowering treatment to prevent heart attack trial (ALLHAT), the largest hypertension trial ever conducted, reported its findings. 21 It was designed to compare the effect of four different first-line antihypertensive drugs on a combined primary end point of nonfatal MI and fatal CHD. In over 40 000 hypertensive patients, initial therapy with the reference drug, a thiazide-like diuretic, chlortalidone, was compared with the ACE inhibitor, lisinopril, the CCB amlodipine and the alphablocker' doxazosin. The ALLHAT population was recruited on the basis of higher CVD risk (many had established CHD or diabetes). The population was elderly and by design included a large proportion of women (47%) and African Americans (32%) (3% were Hispanic black).
The alpha-blocker limb was stopped prematurely after approximately 3 years due to an excess of combined CVD events compared with chlortalidone. This excess was largely due to a reported increase in heart failure, although there was no associated increase in mortality or in the primary endpointdespite a 3 mmHg difference in SBP in favour of chlortalidone.
After an average of about 5 years, there was no difference in the primary outcome or all cause mortality in the remaining three limbs of the trial. For the secondary end point of stroke, there was a 15% excess in the lisinopril limb compared with chlortalidone (P ¼ 0.02), which was compatible with less good BP control in the lisinopril limb of the trial. There was a reported 19% excess of heart failure in the lisinopril limb compared with the chlortalidone limb and in the amlodipine limb (38% excess compared with chlortalidone). Concerns have been raised about validation of this end point. ALLHAT was an important trial which had the potential to influence many guidelines, but the interpretation of the findings require detailed consideration before the unqualified conclusion and recommendations of the authors and the subsequent JNC 7 report 7 are accepted in clinical practice. A detailed critique of this study and an analysis of the results is beyond the scope of the guidelines and the reader is referred to the following commentaries. [171] [172] [173] Following publication of ALLHAT, the second Australian National Blood Pressure study (ANBP2) trial, which for the first time compared a truly low dose of a thiazide diuretic (hydrochlorothiazide 12.5 mg once daily) with an ACE-inhibitor-based regimen, was reported. 168 This trial had several shortcomings, including poor compliance, and produced an equivocal result suggesting that the ACE inhibitor was of borderline superiority in protecting against cardiovascular events. The results appear to contradict those of ALLHAT and are of uncertain value.
In the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study in which treatment with an ARB was compared with a beta-blocker, 12 the losartan-based regimen reduced cardiovascular events compared with the atenolol-based regimen. The difference was largely attributable to a risk reduction in stroke despite there being little difference in BP between groups. These data from the LIFE trial raise the possibility of stroke protection with ARB-based treatments that add to the benefit of BP lowering. However, controversy remains as to whether this reflects less effective stroke prevention afforded by beta-blockade, as suggested by some earlier trial evidence. 167 
Meta-analyses of BP-lowering trials
Since the 1999 BHS guideline, the Blood Pressure Lowering Trialists' Collaboration have conducted two major meta-analyses of BP-lowering drugs. 22, 24 The first published in 2000 examined the effectiveness of 'newer therapies', that is, ACE inhibitor or CCB-based treatments vs conventional therapies (diuretic/beta-blocker-based) and concluded that 'newer therapies' were as effective, but no more effective than conventional therapy at reducing stroke, CHD morbidity or mortality, or all-cause mortality. 22 However, despite its size, this metaanalysis was still underpowered to demonstrate potentially important differences between drug classes with regard to cause specific outcomes. Nevertheless, this analysis confirmed the safety and efficacy of CCB-based therapy at a time when there was controversy about this issue. The 2000 meta-analysis has recently been updated in the second cycle of prospectively designed overviews from the Blood Pressure Lowering Treatment Trialists' Collaboration. 24 This new analysis of 29 trials and 162 341 participants with over 700 000 years of patient follow-up includes the more recent studies such as ALLHAT, ANBP-2, SCOPE and LIFE. Its findings are largely consistent with the 2000 metaanalysis, notably that, in general, the main driver of benefit from BP-lowering therapy is BP lowering per se, and that there is little evidence of additional drug class-specific benefits with regard to major cardiovascular outcomes overall. The caveats to this general conclusion are (1) that CCB-based therapy may be less protective than other agents against the development of heart failure; (2) there may be small benefits of CCB-based therapy, and even larger benefits of ARB-based therapy with regard to stroke prevention over and above the benefits of BP lowering; (3) there may be compelling indications for specific drug classes for target organ protection (see Table 2 ).
BP-lowering drugs and new-onset diabetes
People with hypertension experience a doubling in their lifetime risk of developing type II diabetes. 174 In several recent trials, different rates of the development of new-onset diabetes have been reported with different BP-lowering treatment strategies. 8, 12, 21 In early trials using higher doses of thiazide/ thiazide-like diuretics, impairment of glucose tolerance was observed. 167 Beta-blockers have also been shown to impair glucose tolerance and worsen other metabolic variables. In recent trials, when betablockers have been combined with thiazide/thiazide-like diuretics, new-onset diabetes occurred more frequently (by about 15%) than with regimens based on newer therapies such as ACE inhibitors, ARBs and CCBs. 8, 12, 21 The longer-term consequences of these findings beyond the duration of the trials in which they have been observed are of concern because of the potential of impaired glucose tolerance and diabetes to increase CVD risk.
Recommendations for drug selection in practice-The BHS AB/CD algorithm Hypertension control remains suboptimal in the UK. 43 Most people require more than one drug to control BP, and yet the majority of treated hypertensive patients continue to receive monotherapy. 43 Moreover, the UK has by far the lowest rate of fixed-dose combination therapy use in Europe and BP control rates lag substantially behind those of North America. 162 Hypertension guidelines hitherto have lacked the didactic treatment protocols common to other diseases such as asthma and heart failure, that have provided clear guidance on drug sequencing.
Since the 1999 BHS guidelines, clinical trials have clearly shown that treatment algorithms deliver better BP control than current clinical practice. The BHS has recently published a treatment algorithm (AB/CD) 45 designed to encourage improved BP control. Although randomised, controlled trials have yet to validate this specific algorithm, the recommended combinations are similar to those used in many randomised controlled trials of BPlowering drugs, and involves extrapolation from an understanding of how different drugs work.
The treatment plan that we wish to endorse is modified from the original AB/CD rule. 45 Each letter refers to a BP-lowering drug class 175 and the AB/CD algorithm is illustrated in Figure 3 .
It is important to note that the emphasis is on BP control. The AB/CD protocol is not restrictive and provides a template that allows the use of all classes of antihypertensive drugs. All things being equal and when there are no compelling indications for treatment with a specific class of drugs (see Table 2 ), then the cheapest available drugs should be used.
The theory underpinning the AB/CD algorithm is that hypertension can be broadly classified as 'high renin' or 'low renin', and is, therefore, best initially treated by one of two categories of antihypertensive drug, that is, those which inhibit (ACE inhibitors/ ARBs or beta-blockers) and those which do not inhibit (CCBs or diuretics) the renin-angiotensin system. Renin-profiling studies have demonstrated that younger people o55 years and caucasians tend to have higher renin levels relative to older people (X55 years) or the black population (of African descent). Thus, the A or B drugs which reduce BP at least in part by suppressing the renin-angiotensin system at one point or another are generally more effective as initial BP-lowering therapy in younger caucasian patients. In contrast, CCBs and diuretics are less effective as initial BP-lowering therapy in these patients, and are better used first-line in older caucasians or the black population of any age. [176] [177] [178] Prospective evidence for the recommendations at step 1 arise from crossover studies in younger caucasian patients which found A or B to be almost twice as effective as C or D in reducing BP. 157, 179 A randomised, parallel group study also reported D to be less effective in young caucasians, and that C was more effective (at all ages) than A or B in the black population. 158 The crossover studies permitted recognition of the two main categories of drug response, with correlation coefficients of 0.7 for the responses within each of the pairs, AB and CD, but no significant correlation between responses to drugs from opposite categories-for example, A and C. One other study, using ABPM, also reported a significant correlation between the BP-lowering response to A and B, but not between either of these and C. 155 The correlation data imply that there is little to be gained in efficacy from switching within each pair, for example, from A to B, whereas switching between pairs might enable a patient unresponsive to initial therapy to be controlled on a single drug. On the other hand, when a patient does respond to, but is intolerant of, a drug, it is logical to switch to the other member of the pair-for example, from B to A.
The evidence for recommending C or D in older patients derives from the ALLHAT study which showed that, in older patients, C and D lowered BP more than A (an ACE inhibitor), the difference being most marked in black patients. 21 Less direct evidence comes from a comparison of BP response to drugs in different trials. Outcome trials still in progress, Valsartan Antihypertensive Long-term Use Evaluation (VALUE) and ASCOT will provide direct comparisons within the same trial of the efficacy of C with A (an ARB) or B, respectively.
Turning to combination therapy-steps 2 and 3 in the AB/CD rule-the algorithm is less firmly scientifically based but supported by theory and clinical experience. The theory of combining one each of either A or B with either C or D derives from the respective effect of these categories on the reninangiotensin system. 180, 181 All four of the possible permutations of {A or B} þ {C or D} have been approved by regulatory authorities as fixed-dose combinations. The most widely used combinations which are undoubtedly effective in terms of BP reduction are those of beta blockade and thiazide/ thiazide-like diuretics, ACE inhibitor or ARB and thiazide/thiazide-like diuretics, and beta-blocker and CCB. When fixed-dose combinations replicate the desired treatment plan for a patient and when there is no cost disadvantage to their use, the BHS recommends the use of fixed-dose combinations as a sensible way of reducing the number of medications and thereby potentially improving adherence with therapy.
The AB/CD algorithm includes B in brackets. This is to emphasise the fact that each of the recent outcome trials that have reported the onset of new diabetes as a secondary end point has found a significant excess of new-onset diabetes in patients receiving an 'older' compared with a 'newer' class of drug (see above). 9, 12 To what extent this is because older drugs enhance the already increased risk of developing type II diabetes in people with hypertension, and/or whether 'newer' drugs reduce that risk, is unclear. Retrospective studies of treated hypertensive cohorts have strongly implicated beta- Figure 3 Recommendations for combining blood pressure lowering drugs/ABCD rule. 45 Guidelines for management of hypertension B Williams et al blocker therapy as potentiating the risk of developing new-onset diabetes. This is supported by the findings of the LIFE trial in which there was a significant 15% excess of new-onset diabetes over 5 years when beta-blocker-based therapy was directly compared to ARB-based therapy. All other treatments being equivalent, including the used of thiazide/thiazide-like diuretics in approximately 90% of patients in both arms of the trial. Whatever the mechanism, this is not cosmetic and the potential long-term effects of diabetes behove us to take the implication of this finding seriously. The ongoing ASCOT trial 182 will provide much-needed randomised controlled evidence as to whether these concerns are valid.
One post hoc analysis has suggested that the increased risk of new-onset diabetes is confined to patients with an elevated blood glucose at baseline, low HDL-cholesterol, obesity or genetic (family or ethnic) predisposition to diabetes. 183 Another suggested that the risk is confined to patients receiving the higher dose of older drug. 184 Thus, in patients at especially high risk of developing diabetes, that is, (1) strong family history of type II diabetes, (2) obesity, (3) impaired glucose tolerance and/or features of the metablic syndrome, or (4) specific ethnic groups, such as in the South Asian community, it is advisable to limit the dose of (B) and not to combine these drugs, particularly with a diuretic.
At step 3, we recommend combining A or (B) with C and D. This triple therapy combination has been used in many of the clinical outcome trials described earlier. Moreover, this triple therapy approach can be achieved by using only two tablets if fixed dose combinations are used, for example, BD þ C, or AD þ C.
In patients with more resistant hypertension, advice is even more anecdotal or theory-based A þ B þ C þ D may be effective. Alternatively, it is at this stage that the addition of alpha blockade may be of particular use. Many patients with resistant hypertension may be helped by further elimination of sodium, and in particular, impressive BP lowering has been reported anecdotally with the use of the aldosterone antagonist spironolactone.
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Dosage
The drug formulation used should ideally be effective when taken as a single daily dose. An interval of at least 4 weeks should be allowed to observe the full response, unless it is necessary to lower BP more urgently. The dose of thiazide/ thiazide-like diuretic should not be titrated up, 187 whereas other drug classes should be titrated according to the manufacturers' instructions. When the first drug is well tolerated but the response is insufficient, as is the case in over half of all hypertensive patients, the options are to substitute an alternative drug or to add a second drug.
Substitution of an alternative drug is appropriate when hypertension is mild and uncomplicated and the response to the initial drug was small. In more severe or complicated hypertension, it is safer to add drugs stepwise until BP control is attained. Treatment can be stepped down later if the BP falls substantially below the optimal level.
Other routine medications for hypertension patients
Lipid-lowering agents Two trials-ALLHAT 188 and ASCOT 49 -have recently reported cardiovascular outcomes associated with the use of statins, specifically among patients with hypertension. Prior to these two recent trials, other randomised controlled trial data were available from analyses of the hypertensive subgroups from lipid-lowering trials in secondary prevention, [189] [190] [191] [192] primary prevention, 193, 194 and a mixture of primary and secondary prevention. 48, 194 The Heart Protection Study (HPS) 48 included over 20 000 patients, 41% of whom were hypertensive, and the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) trial 195 included only elderly patients, 62% of whom were hypertensive. Like HPS, PROSPER mainly included patients with established vascular disease. Analyses of the hypertensive subgroups from all these trials show that the benefits of lipid lowering with statins in terms of preventing major coronary events are similar for hypertensive and normotensive patients.
Somewhat more surprising, and of special importance to the hypertensive population, is the finding that, in the statin trials, overall stroke risk was reduced by an average of 15 and 30% in primary and secondary prevention settings, respectively, 196 although no such benefit was observed in the PROSPER trial. 195 The ALLHAT-LLT trial compared the impact of 40 mg pravastatin with usual care in over 10 000 hypertensive patients. 187 The differential effect of pravastatin on total and LDL-cholesterol of 9% and 17%, respectively, was smaller than expected, due to extensive statin use in the usual care group, and was associated with a nonsignificant 9% reduction in fatal CHD and non-fatal MI and a 9% reduction in fatal and nonfatal stroke. There was no apparent impact on all-cause mortality, which was the primary end point of the trial. By contrast, the results of the ASCOT-LLA trial, 49 which also included over 10 000 hypertensive patients at a modest background risk of cardiovascular disease, showed highly significant cardiovascular benefits (36% reduction in the primary end point of fatal CHD and nonfatal MI and 27% reduction in fatal and nonfatal stroke) associated with the use of atorvastatin 10 mg compared with placebo in patients with total cholesterol p6.5 mmol/l. These highly significant benefits were apparent despite exemplary BP control. The apparent difference in effect seen in the ALLHAT and ASCOT trials probably reflects the greater relative difference in total and LDL-cholesterol achieved among the actively treated group in the ASCOT trial (24% and 35%, respectively).
Recommendations regarding the use of lipid-lowering therapy for patients with hypertension may be subdivided into those relating to secondary and to primary prevention.
Secondary prevention: Based on the results of the HPS 48 and other secondary prevention trials, [189] [190] [191] [192] all patients up to the age of at least 80 with total cholesterol 43.5 mmol/l with active CHD, peripheral arterial disease or a history of ischaemic stroke should receive a statin. In light of the high coronary event rates observed among many patients with type II diabetes, 78 and the high long-and short-term fatality rates for such patients, it is recommended that patients with type II diabetes-diagnosed at least 10 years ago and/or aged 50 years or moreshould be considered as CHD risk equivalents 197 as far as lipid lowering is concerned, and hence should be treated as for secondary prevention. Other patients with type II diabetes could be considered as for primary prevention on the basis of an estimated risk threshold, 80 but for simplicity regarding treatment threshold purposes, it is recommended to consider such patients as 'coronary equivalents'. Therapy should be titrated to lower total or LDL-cholesterol reduction of by 25% or 30%, respectively, or to o4.0 mmol/l or o2.0 mmol/l, respectively, whichever is the greater reduction. This should be regarded as the optimal therapeutic goal, but in view of current treatment practices we recommend an audit standard of total cholesterol o5.0 mmol/l or LDL-cholesterol o3.0 mmol/l with a total or LDL-cholesterol by 25% or 30%, respectively.
Primary prevention: Randomised placebo-controlled trial evidence has demonstrated significant benefits of statin therapy among normotensive and hypertensive adults with an estimated mean 10-year CHD risk of as low as 6%. 194 However, the majority of adults over the age of 40 in the UK are at or above a 6% 10-year CHD risk, and consequently it is not financially feasible nor conceptually ideal to treat all people at and above this level of risk. Only 1% of patients in the HPS 48 were hypertensive and did not have either a history of a cardiovascular event, active vascular disease and/or diabetes, and hence this trial does not supply a robust database on which to make recommendations for primary prevention of CVD in hypertensive patients. In view of the results of the ASCOT trial 49 and other currently-available trial data, 194 it seems reasonable, in the interests of simplicity, to treat with a statin all those patients at least up to the age of 80 years with a total cholesterol 43.5 mmol/l, who have an estimated 10-year CVD risk of 20% or more. In reality, this would mean considering statin therapy in most hypertensive patients (especially men) over the age of 50 years. As resources allow, a rationale for lowering this threshold could be made based on trial evidence. 49, 194 Target levels should be as for secondary prevention. The vast majority of patients will reach recommended total cholesterol or LDL-cholesterol targets using statin drugs at appropriate doses in combination with lifestyle measures. 198 For patients who do not reach targets or whose HDL-cholesterol or triglyceride levels remain abnormal (eg o1.0, 42.3 mmol/l, respectively) despite reaching LDL targets, referral to lipid specialists may be indicated for consideration of the addition of alternative lipidlowering therapy. No trial data are currently available to advise whether in those patients, such as many type 2 diabetics, whose primary lipid abnormality is a low HDL-cholesterol and raised triglycerides, the use of a fibrate might be preferable to a statin. However, on currently available evidence, statins at suitable doses should be the drugs of choice.
43,156-169
Aspirin Since publication of the 1999 BHS guidelines, no new evidence to guide practice regarding the use of aspirin for hypertensive patients has been produced. Hence, the recommendations made at that time remain unchanged (see Box 9) . In summary, all patients suitable for secondary preventive strategies, including those with type II diabetes of greater than 10-years duration, or over age 50, have a sufficient level of CVD risk to benefit from aspirin therapy, and should be considered for low-dose aspirin (75 mg/ day) unless they have specific contraindications to aspirin use. For primary prevention, the balance of Guidelines for management of hypertension B Williams et al benefits vs harm mandate that patients need to be aged over 50 years and have a CVD risk level X20% over 10 years to shift the balance in favour of benefit. Thus, for primary prevention, low-dose aspirin (75 mg/day) should only be offered to hypertensive patients aged over 50 years whose BP has been controlled to the audit standard (o150/90 mmHg) and who have a baseline CVD risk X20% over 10 years and no contraindications to aspirin use.
Vitamins
Good laboratory-based evidence suggest that antioxidant vitamins may play an important role in providing protection against the atherosclerotic process. 199 However, to date, randomised trial data overall have shown no benefits in terms of cardiovascular morbidity and mortality associated with the use of vitamins A, C or E. Most recently, the HPS, 200 which included over 20 000 subjects, 41% of whom were hypertensive, showed no benefits whatsoever-cardiovascular or otherwise-associated with daily antioxidant supplementation of 600 mg vitamin E, 250 mg vitamin C and 20 mg betacarotene. Therefore, we do not recommend that vitamin supplementation should be used with any expectation of either reducing BP or CVD risk.
Special patient groups
Hypertension in the elderly
Hypertension the Historically, the elderly have been neglected in terms of appropriate risk factor assessment and hypertension management, although trial data show that older people have benefited as much if not more so from such interventions as younger individuals. 201 In the UK, CHD and stroke remain the major causes of death in people over the age of 65 years, with hypertension the commonest treatable risk factor. It is well recognised that ageing in Westernised societies is associated with a rise in SBP across the whole age range, while DBP increases up to the age of about 60 years, plateaus, and then falls, resulting in an age-related increase in pulse pressure and ISH.
It is important to note that older people show greater BP variability, and thus it is particularly important that multiple measurements are taken on several occasions to confirm the diagnosis of hypertension. Seated and standing measurements are important during the initial assessment and after initiating drug therapy, because of the high prevalence of orthostatic hypotension in this age group. In older people with significant orthostatic hypertension, that is, SBP, falls X20 mmHg with postural symptoms, treatment may need to be titrated to the standing BP values.
Hypertension is common in older people and, even using the more conservative definition (X160/ 95 mmHg), it is estimated that more than 50% of the 12 million people in the UK over 60 years are hypertensive. If hypertension is defined as X140/ 90 mmHg, over 70% will be hypertensive, the majority of these patients having ISH. 43 It is obvious that with the very high prevalence of hypertension in this age group and the rapidly increasing numbers of older people in most populations, especially those in the 75 þ age group, raised BP levels are an enormous public health problem.
Hypertension cannot be considered in isolation irrespective of age, and it is important that overall CVD risk is assessed when making decisions on treatment (see Figure 1) . Lifestyle measures should be offered to all older people with hypertension and are just as effective as they are in younger people. 100 The benefits of drug treatment for hypertension, including ISH, in those aged up to the age of 80 years, have been clearly demonstrated in randomised controlled trials. However, the absolute benefits of treatment are much greater in older people because of their increased absolute risk. Some studies have also suggested that the cognitive impairment associated with increasing age can also be reduced by treatment, 202 an important consideration in this age group.
Thiazide/thiazide-like diuretics are especially effective at lowering BP in older people, as are dihydropyridine CCBs. 169, 203 Moreover, thiazide/ thiazide-like diuretics and CCBs have been shown to be effective at reducing cardiovascular morbidity and mortality in older people with hypertension or ISH. 167, 169 A recent meta-analysis has suggested that beta-blockers may not be as effective as thiazide/ thiazide-like diuretics at reducing stroke deaths, CHD events or all-cause mortality in older people. 204 Consistent with this conclusion, ARB-based therapy (losartan) was recently shown to be substantially more effective than beta-blocker-based therapy (atenolol) at reducing the risk of stroke and cardiovascular mortality in older people with ISH. 205 The routine use of beta-blockers to treat high BP in older people should be limited unless there are specific indications, for example, post MI, angina or heart failure. Most older people will need more than one BP-lowering drug to control their BP and logical combinations are outlined in the AB/CD algorithm ( Figure 3) .
The benefits of BP-lowering therapy in people over the age of 80 years have not yet been established. A recent meta-analysis of intervention trials that included patients aged over 80 years concluded that active treatment reduced stroke and CHD events (both fatal and nonfatal), but no significant effect on overall mortality was apparent, although available data are too few as yet to evaluate this end point. 206 The ongoing HYpertension in the Very Elderly Trial (HYVET) has been designed to assess the safety and efficacy of antihypertensive therapy in the very elderly (80 þ years). 207 Until such data become available, we recommend that those who reach 80 years of age while on treatment should probably remain on therapy, especially if there is evidence of TOD or they have other significant CVD risk factors such as diabetes. For those aged over 80 years at the time of diagnosis of hypertension, no clear guidance can be given. However, in such circumstances, treatment decisions are best, based on consideration of the presence of other co-morbidities.
Hypertension in the young
There is little evidence to guide management of patients in 'younger patients with hypertension', that is, younger than the lowest age used in the Framingham-based risk calculator, namely 32 years. In those with stage 1 hypertension, that is, 140-159/ 90-99 mmHg, even up to the age of 49 years (the minimum age assigned by the risk tables in Figure 2) , it is almost impossible for a nonsmoker to achieve an absolute CVD risk X20%/10 years, unless diabetic or markedly hyperlipidaemic (total cholesterol:HDL ratio 47.0). Precisely, because of this low absolute level of CVD risk, these patients will never be included within, or contribute many events to an outcome trial. Importantly, although these patients have a low absolute risk, they have a high risk of strokes and CHD relative to their peers. 82 Moreover, Framingham data show a steep rise in SBP and DBP over 10 years in 30-year old people within the top quartile of BP, and it can therefore be surmised that a young patient who is already hypertensive will, if left untreated, become more treatment resistant later in life. Although the hypertension in younger people may appear too mild to treat, it is not benign and it is worth reflecting on the fact that the underlying diathesis is sufficiently severe to have declared itself so young.
The profile of hypertension is also different in younger people. Diastolic hypertension is more common than it is in older people, and appears to be just as strong as a predictor of future cardiovascular events as SBP in this younger age group. With regard to SBP, when it is elevated in younger people, it heralds the onset of ISH with ageing, suggesting that large artery stiffening may be a consequence of untreated systolic hypertension in the young. 208 It is emphasised that, although treatment of stage 1 hypertension in younger people is often delayed because of their low absolute CVD risk over 10 years, it cannot be assumed that subtle and progressive vascular damage occurring in the untreated younger hypertensive patient is necessarily reversible.
One solution might be to calculate the lifetime, rather than 10-year, risks for younger patients. However, such actuarial tables, incorporating other risk factors, are not readily available. We therefore draw attention to the need to be circumspect about applying the thresholds in Figure 1 to treatment decisions in younger patients-particularly those in their early 30 s or younger, who will be exposed to more than a decade of increasing BP before their BP or absolute CVD risk reaches the recommended treatment thresholds for people with stage 1 hypertension. Given the lack of evidence from outcome trials at this younger age, and the unlikelihood that it will ever emerge, it is reasonable to reach a decision jointly with the patient, balancing the inconvenience and cost of treatment with their attitude to the potential benefits of treatment. Unlike their older counterparts, the younger patient can legitimately balance long-term risks against inconvenience of early treatment initiation. Whatever decision is reached, it is important that these patients are not lost to follow-up.
It is also important to note that secondary causes of hypertension are more common in younger people presenting with hypertension. For these reasons, referral for more specialised evaluation should be considered (see Table 3 ). Secondary hypertension should, in particular, be suspected if patients do not respond to the initial treatment recommendations for younger patients according to the AB/CD rule ( Figure 3 ).
Hypertension and stroke
Stroke mortality has been falling in the UK for the past three decades and deaths from cerebral haemorrhage may have been falling for even longer. 209 This reduction probably results from a combination of a decrease in stroke incidence and severity, and in the case-fatality rate. However, increased survival rates and an ageing population has resulted in an increased burden of stroke in the UK population. In the UK, there are still over 120 000 strokes per annum, of which 20% are recurrent stroke. Approximately 80% of all strokes are due to cerebral infarction from large and small (lacunar) vessel disease as well as cardioembolic sources. In all, 10% of strokes result from cerebral haemorrhage, and the rest are related to subarachnoid haemorrhage and 'stroke of unknown causes'. Overall, 20% of people die within the first few months of a stroke, and up to 35% will be dependent at 1 year. 210 Although the majority of deaths within the first few months of stroke onset are directly related to the initial event, mortality after 1 year is often due to CVD other than stroke recurrence. 211 Hypertension remains the most important treatable risk factor for the prevention of stroke and its recurrence, and antihypertensive therapy significantly reduces the risk. The relation between BP levels immediately poststroke and outcome (in terms of death and disability or stroke recurrence) is less clear, as is its clinical management. Half of all stroke patients will have a history of hypertension and up to 40% will be on antihypertensive treatment when their stroke occurs. 212 After acute cerebral haemorrhage or infarction, casual BP levels are usually increased, with more than 80% of patients having levels X160/95 mmHg within the first 48 h of ictus. These values usually decrease spontaneously in the subsequent 10-14 days, the falls being most marked in those who continue their antihypertensive drugs. 213 The initial increase in BP after stroke may in part be simply due to the stress of hospitalisation, but other mechanisms may also be responsible. 214 Observational studies reporting poststroke outcome in relation to initial casual BP levels are inconsistent. [215] [216] [217] However, using 24-h BP monitoring, and thus reducing the variability of BP measurement in the acute situation, it has been reported that for every 10 mmHg increase in 24-h SBP levels, the likelihood of death or dependency at 30 days post-ictus is almost doubled. 218 In contrast, the International Stroke Trial 219 reported a J-shape relation between initial BP and outcome, with early deaths increasing by 18% for every 10 mmHg of admission of SBP below 150 mmHg and by 4% for every 10 mmHg above 150 mmHg. It is not too surprising that low BP values are related to an adverse prognosis as they are often associated with large cerebral infarcts (total anterior cerebral artery occlusion) or concomitant severe cardiac disease.
There are potential pros and cons for both raising and lowering BP in the acute post-ictal situation. However, to date, there have been very few trials of either pressor or depressor interventions in the acute stroke period. Small studies of beta-blockers and CCBs used immediately post-stroke have shown no benefit, but these studies were too small to draw firm conclusions. 220 The recently reported Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) Trial 221 did suggest that the ARB candesartan may be of benefit in those with markedly elevated BP levels (X200/110 mmHg) within the first 48 h of cerebral infarction, but the findings of this small trial need confirmation. Whether antihypertensive treatment should be continued or stopped immediately post-stroke is also unclear and the subject of a major ongoing trial. 214 Presently, it is not possible to provide clear guidance on the clinical management of BP in the immediate (o48 h) post-stroke period. It has been suggested that treatment to lower BP is appropriate when BP is persistently elevated immediately post-stroke (SBP4220 mmHg or MAP4130 mmHg), although there are no clinical trial outcome data to support this view. 222 Agents such as labetalol, nitrates and sodium nitroprusside have been used to lower BP acutely in stroke patients, especially in situations where thrombolysis is being undertaken. These antihypertensives can be given by nonoral routes, an important consideration given that 30% of stroke patients are initially dysphagic. Other stroke patients for whom immediate BP reduction may be beneficial include patients with cerebral haemorrhage, those with cardiac and vascular emergencies such as hypertensive encephalopathy, aortic or carotid dissection, acute MI or angina.
Almost half of all stroke survivors will have a raised BP 1-6 months after stroke onset, and most observational studies have shown that higer BP levels at this stage are associated with an increased risk of stroke recurrence and the subsequent development of CHD events. 223 To date, only two small studies, 224, 225 published more than 30 years ago, have assessed the benefit of pharmacological BP reduction in post-stroke subjects restricted to those who had hypertension, and they produced conflicting results. Although many of the large, placebocontrolled, BP-lowering trials in hypertension have included stroke patients, the evidence for benefit of treatment in these small subgroups has not been made available. There are, however, available data from seven randomised controlled intervention trials of BP reduction in stroke/transient ischaemic attack (TIA) patients who were not necessarily hypertensive. 16, [224] [225] [226] [227] [228] [229] Indeed, the majority of these studies included patients who were either normotensive or who had treated and controlled hypertension at entry. The majority of these studies were based on a diuretic and/or an ACE inhibitor as firstline agent with no particular BP target set, and the achieved BP reductions compared to placebo were quite modest (10/5 mmHg). Meta-analysis has shown that treatment significantly reduces the odds ratio for fatal and nonfatal stroke recurrence (0.74 95% CI 0.66-0.82), as well as for all major cardiovascular events (0.77, 0.70-0.84). 214 The PRO-GRESS Study is the largest study to show the benefits of BP reduction (using an ACE-inhibitor, perindopril with or without a thiazide-like diuretic indapamide) on stroke recurrence and major cardiovascular event rate in patients with a history of stroke or TIA irrespective of baseline BP level on entry to the study. 16 By inference, most patients with established CVD would benefit from BP lowering; hence conventional BP thresholds and targets do not apply (see Box 5) , and the lowest BP tolerated is recommended. No firm recommendations can be given as to whether one class of antihypertensive agents is better than another in this situation, but the acute beta-blocker-based regimens seem to do poorly compared to those involving a thiazide/thiazide-like diuretic and/or ACE-inhibitor therapy. 214 When treatment should be started or restarted is also unclear, but practice is usually to initiate therapy a couple of weeks after the acute event. Whether a more aggressive stance should be adopted with regard to BP control in patients with primary intracerebral haemorrhage is also uncertain.
As with the general management of hypertension, other factors in stroke and TIA patients must also be considered. There is convincing evidence that patients who have had a TIA or cerebral infarct should receive an antiplatelet agent. Aspirin (75-300 mg daily) will reduce the risk of subsequent cardiovascular events by about 11% following acute stroke (irrespective of admission BP levels) and by 20% in those with a past history of ischaemic stroke. 230 For those stroke patients in atrial fibrillation, anticoagulation will reduce the incidence of a further stroke by over 60% (paying careful attention to control of hypertension if present 231 ), and statin therapy lowers risk of subsequent major vascular events by over 20% in those with TC levels 43.5 mmol/l. 48 In patients with symptomatic severe carotid artery stenosis (X70% but without near occlusion), carotid endarterectomy reduces subsequent stroke by 40% 232 (Box 10).
Hypertension in people with diabetes
When compared to people without diabetes, hypertension (defined as a BP X140/90 mmHg) is twice as common in people with diabetes. In type I diabetes, the excess prevalence of hypertension is strongly related to the presence of incipient or overt nephropathy. In type II diabetes, hypertension is very common with prevalence rates reaching 80% in many European countries. 233 Hypertension in diabetes is characterised by an earlier onset of systolic hypertension and a higher prevalence of ISH at any age when compared to people without diabetes. In type II diabetes, hypertension is more common in women than men and the age-related increase in SBP is steeper in women. 233 In addition to being very common, hypertension greatly increases the already elevated CVD risk in people with diabetes. Diabetes increases the risk of coronary disease two-fold in men and four-fold in women. 27, 81, 234 The combination of hypertension and diabetes doubles the risk of developing microvascular and macrovascular complications, and doubles their risk of mortality when compared to nondiabetic people with hypertension. 27, 81, 234 Benefits of BP lowering in people with diabetes The impressive benefits of BP lowering in reducing or preventing an aggregate of major cardiovascular events, including heart failure, cardiovascular death and/or total mortality in people with diabetes, has been established in many clinical trials which have compared 'more' with 'less' intensive BP lowering. [27] [28] [29] [30] [235] [236] [237] In addition, 'more versus less' BP lowering has also been shown to significantly reduce the progression of retinopathy, albuminuria and the progression of nephropathy. [27] [28] [29] [30] [235] [236] [237] Thresholds for intervention with BP-lowering therapy in people with diabetes The previous BHS guidelines recommended that BP lowering with drug therapy is indicated in people with type I or type II diabetes when the SBP is X140 mmHg and/or the DBP is X90 mmHg. 3 This recommendation is endorsed by the present guideline and is consistent with International consensus. 7, 238 BP treatment goals in people with diabetes and hypertension Population-based observational data suggest that, when compared to the nondiabetic population, CVD risk is elevated in people with diabetes at every level of BP and well into the conventional normotensive range. 239, 240 Moreover, there appears to be no threshold below which risk substantially declines. Furthermore, from a pathophysiological perspective, people with diabetes exhibit disturbances to BP regulation and vascular function that increases their vulnerability to hypertensive injury. 241 These observations, allied to the clinical trial evidence that more intensive BP lowering is beneficial in reducing cardiovascular and diabetes-specific events in people with diabetes, have led to the recommendation that BP treatment targets should be lower in people with diabetes. International guidelines currently recommend a BP treatment target of o130/80 mmHg for people with hypertension and diabetes. 7, 238 With regard to this target, three points should be emphasised:
(1) Hypertension, especially SBP, is more difficult to control to target in people with co-existing diabetes.
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(2) Most clinical trials have failed to achieve the recommended BP target, and it has been especially difficult to lower SBP to below 140 mmHg.
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(3) Control of DBP is less problematic and the main focus should be on SBP control, as many of these patients (especially with type II diabetes) will have ISH.
The recommendation that BP should be lowered to o130/80 mmHg in people with diabetes and Box 10 Cerebrovascular disease
K
Increasing blood pressure levels are a significant risk factor for primary stroke and recurrence even in the very elderly. K Following acute stroke blood pressure levels are frequently raised and fall spontaneously over the next few days. Both high and low blood pressure levels immediately post-stroke are associated with an adverse prognosis. K There is no evidence yet as to whether antihypertensive drugs should be started immediately after stroke or if current medication should be continued in the acute post-ictal phase. K Thiazide/thiazide-like diuretics and/or angiotensin-converting enzyme inhibitors reduce the risk of stroke recurrence and major cardiovascular events by about 20-30% in those with a history of stroke or transient ischaemic attack whether normotensive or hypertensive at follow up. These benefits, irrespective of baseline BP, are more likely to be due to BP lowering. 16, 228 K To realize the full potential in both primary and secondary stroke prevention other cardiovascular disease risk factors must be treated.
Guidelines for management of hypertension B Williams et al hypertension is not yet firmly supported by clinical trial evidence. Nevertheless, there is no evidence from trials that have achieved lower BPs on treatment that such aggressive BP lowering would increase CVD risk or cause harm-on the contrary benefits appear to be the most likely outcome. Based on the available evidence, a first target for all patients with diabetes should be to reduce BP to below 140/80 mmHg. 3, 81 Thereafter, further cardiovascular benefit would be expected if the BP could be lowered to an 'optimal target' of o130/80 mmHg.
Treatment of hypertension in people with diabetes: choice of therapy This has been an area of great controversy, myths and misconceptions. 244 Most studies comparing drug classes for the treatment of hypertension in people with diabetes have been relatively small, often substudies within larger trials. There has been controversy about the safety and efficacy of CCBs at preventing cardiovascular events in people with diabetes. 26 There has also been a reluctance to use thiazide/thiazide-like diuretics because of perceived adverse effects on insulin sensitivity and metabolic parameters. Many of these concerns have been allayed by recent clinical trial results. 21 International guidelines have uniformly recommended ACE inhibitors as first-line therapy for people with diabetes and hypertension. 7, 238 However, it should be recognised that the evidence supporting this recommendation is limited. The recently reported ALLHAT study included over 12 000 people with hypertension and type II diabetes. 21 This study compared a thiazide-like diuretic (chlortalidone) with a CCB (amlodipine) or ACE inhibitor (lisinopril) as first-line therapy, and did not show superiority of the ACE inhibitor over the thiazide/thiazide-like diuretics at reducing coronary or cardiovascular events or mortality in people with type II diabetes. ALLHAT, added to other recent studies, 8, 9, 11 helps dismiss concerns about the safety and efficacy of CCBs and thiazide/thiazide-like diuretics for the treatment of hypertension in people with diabetes. 21 The ARBs also represent an evidence-based strategy for renin-angiotensin system blockade in people with diabetes and hypertension, and the Losartan Intervention for Endpoint (LIFE) study demonstrated that losartan-based therapy was more effective than atenolol-based therapy at reducing cardiovascular events, cardiovascular death and total mortality in the cohort of people with type II diabetes. 13, 245 Taken together with data demonstrating renoprotection with ARBs in people with type II diabetes, [18] [19] [20] the evidence for cardiorenal protection is marginally more substantial for ARBs than ACE inhibition in type II diabetes. In type I diabetes, there is more evidence for renoprotection with ACE inhibition, but there are no substantial data confirming cardiovascular protection with ACE inhibition, beyond the impact of improved BP control. 246 Need for combination therapy Good BP control is key to cardiovascular and renal protection in people with diabetes. Almost all patients with hypertension and diabetes will require a combination of BP-lowering drugs to achieve the recommended BP targets-with many requiring three or more drugs. 243, 244 This combination is likely to include a thiazide/thiazide-like diuretic. 21 The evidence for renin-angiotensin system blockade especially for nephroprotection (and reduction in surrogates such as proteinuria) and cardiovascular protection strongly support the use of an ACE inhibitor or ARB 13, [18] [19] [20] 245, 246 as part of the treatment cocktail, especially in those patients at higher CVD risk by virtue of established TOD. When there are no cost disadvantages, the combined drugs should be used as a fixed-dose combination to reduce the number of medications. Other drugs will be required to achieve BP targets in most people and longer acting CCBs, beta-blockers and alpha-blockers are all suitable therapies. In patients with renal impairment and/or oedema, a loop diuretic may be required as an alternative to, or in addition to, a thiazide/thiazide-like diuretics.
Diabetic nephropathy Type 1 diabetes and diabetic nephropathy: BP reduction and ACE-inhibitor treatment slow the rate of decline of renal function in overt diabetic nephropathy 246 and delay progression from the microalbuminuric phase to overt nephropathy. [247] [248] [249] The ACE inhibitors may have a specific renoprotective action in patients with incipient or overt type I diabetic nephropathy, and are recommended as initial therapy. If ACE-inhibitor treatment has to be discontinued because of persistent cough, an ARB is the recommended alternative. The ACE inhibitor should be titrated to the maximum dose recommended and tolerated. Combinations of antihypertensive drugs are invariably required to achieve recommended BP targets. Low-dose thiazide/thiazide-like diuretics, CCBs, beta-blockers and alphablockers are all possible add-on drugs. Type I diabetic subjects with persistent microalbuminuria or proteinuria and any level of BPs are likely to benefit from ACE inhibition (or ARB) titrated to the recommended maximum dose. 246, 247, 250 It remains unclear whether this benefit accrues from blockade of the renin-angiotensin system per se, or the associated BP reduction. 251 The target BP is o130/ 80 mmHg. 81, 247 Type II diabetes and diabetic nephropathy: Since the previous BHS guidelines, there is now much more evidence on which to guide practice in people with type II diabetes and nephropathy. Hypertension accelerates the decline of renal function in type II diabetic patients with established nephropathy. 247, 252 Moreover, antihypertensive therapy slows the progression of nephropathy in patients with type II diabetes. 247 ACE inhibitors have an antiproteinuric action and delay progression from microalbumi-nuria to overt nephropathy, 247, 249, 253 but it is less clear whether they have a specific renoprotective action beyond BP reduction in overt nephropathy complicating type II diabetes. There is now good evidence that ARB-based antihypertensive therapy can delay the progression of microalbuminuria to overt nephropathy (proteinuria) 18 and the progression of overt nephropathy to endstage renal disease. 19, 20 This benefit of ARB-based therapy at delaying the progression of nephropathy in type II diabetes is complementary to the more substantial benefits achieved by improved BP control. 254 Reducing cardiovascular disease risk in people with diabetes The high CVD risk of people with diabetes and hypertension (especially type II diabetes), and the fact that many have established CVD at diagnosis means that people with type II diabetes and hypertension will also benefit from statin therapy, irrespective of their baseline cholesterol. 49, 255 We recommend the routine use of statin therapy in people with type II diabetes complicated by hypertension. For people with type I diabetes, there is insufficient data to guide practice with regard to statins, but given the high rates of CVD among the population it seems reasonable to treat them as per type II diabetes. Low-dose aspirin is also indicated for primary prevention of CVD in patients aged over 50 years when BP is controlled to o150/90 mmHg and when 10-year CVD risk exceeds 20%. This multifactorial approach should be complemented by efforts to optimise glycaemic control and continued lifestyle measures because many diabetic patients, particularly those with type II diabetes, are overweight and would benefit substantially from weight reduction, increased exercise output and dietary sodium restriction.
Renal disease and hypertension
Renovascular disease (renal artery stenosis): this is relatively uncommon, but is a potentially curable cause of secondary hypertension. Routine investigation of all hypertensive patients is not justifiable, but doctors should be aware of important clues suggesting renovascular disease. These are: onset of hypertension before the age of 30; documented sudden onset of hypertension or sudden worsening of hypertension in middle age; accelerated (malignant) hypertension; resistant hypertension (to a Xfour drug regimen); renal impairment of unknown cause; large elevation of serum creatinine, especially with marked BP reduction by ACE inhibitor or ARB treatment (X30% increase of creatinine); 256 peripheral vascular disease or severe generalised atherosclerotic disease; recurrent 'flash' pulmonary oedema or heart failure with no obvious cause.
Where there is a high index of suspicion of renovascular disease, referral for expert advice should be considered.
Renal parenchymal disease: this accounts for hypertension in approximately 5% of people. Hypertensive patients with elevated serum creatinine or proteinuria at their initial assessment may have renal parenchymal or obstructive renal disease, and should be referred for specialist evaluation. Accelerated (malignant) hypertension may also be a consequence of renal parenchymal or vascular disease, and requires immediate hospital treatment because it causes rapid loss of renal function that can be irreversible if untreated. Apart from accelerated hypertension, hypertension per se is not a prominent cause of advanced renal disease, even though elevated BP is known to accelerate the agerelated decline in glomerular filtration rate (GFR).
BP thresholds, targets and choice of therapy in people with renal disease and hypertension BP is an important determinant of the rate of decline of GFR with age, and this becomes significant and important in people with evidence of renal impairment. Two factors are important in preserving residual renal function in people with diabetic and nondiabetic renal disease: (1) BP control and (2) blockade of the renin-angiotensin system.
The threshold for antihypertensive treatment in the previous guideline for patients with persistent proteinuria and/or renal impairment was X140 mmHg systolic, and/or X90 mmHg DBP. 3 This recommendation is unchanged.
Optimal BP control is defined as o130/ 80 mmHg, 257, 258 and reducing BP to o125/75 mmHg may produce additional benefit in patients with chronic renal disease of any aetiology associated with proteinuria of X1 g per 24 h. 258, 259 It is emphasised, however, that this concept that 'lower is better' for patients with renal disease and hypertension is based on limited evidence, and is largely extrapolated from retrospective analysis of clinical trial data. 258, 259 Moreover, the African American Study of Kidney Disease (AASK) did not demonstrate that a lower target BP (128/78 mmHg) was better than less tight BP control (141/85 mmHg) at preserving renal function in African Americans with nondiabetic chronic renal disease. 33 The validity of this finding and its relevance to the UK population is unclear.
Choice of antihypertensive therapy: blockade of the renin-angiotensin system has been widely advocated as having 'renoprotective' benefits beyond that of BP control alone. 259, [260] [261] [262] [263] There are limited data on the renoprotective effects of ARBs in nondiabetic patients with chronic renal disease. In the CO-OPERATE study, the combination of ARB and ACE inhibitor was more effective than the ARB or ACE inhibitor alone in protecting renal survival. 264 However, this was a small study and further work in this area is needed. Meta-analyses examining the renoprotective effect of ACE inhibitors in patients with nondiabetic renal disease have concluded that there is benefit of ACE inhibition beyond that attributable to BP lowering. 262, 263 This is most notable in people with overt proteinuria. 33, 260, 262, 263 Specific blockade of the reninangiotensin system may be less important than BP control per se in preventing the development of renal impairment, in the progression of less advanced renal disease or in those without overt proteinuria. 21 ACE inhibitors may not be renoprotective beyond their BP-lowering effect in those with polycystic kidney disease. 262 Blockade of the renin-angiotensin system (ACE inhibition or ARBs) as monotherapy will not be sufficiently effective in controlling BP in patients with renal disease and hypertension. Additional therapy should include a thiazide/thiazide-like diuretic. In patients with oedema or more advance renal impairment, for example, serum creatinine 4200 mmol/l, thiazide/thiazide-like diuretics may be ineffective and a loop diuretic (eg furosemide) may be required, often in higher doses than used conventionally. Most people will still require additional antihypertensive therapy. Dihydropyridine CCBs are an effective additional therapy and other classes of drug can be added as required.
Renal disease as a cardiovascular disease risk factor
It is now well recognised that even mild persistent elevations in urinary albumin excretion (even below the threshold currently used to define microalbuminuria) and/or mild elevations in serum creatinine, prior to initiation of antihypertensive therapy, are strong predictors of premature cardiovascular morbidity and mortality. 234, [265] [266] [267] [268] [269] [270] As such, most patients with renal disease and treated hypertension have established TOD (for TOD definition see Table 1 ), remain at substantial CVD risk, and would benefit from statin therapy and aspirin.
Oral contraceptives (OCs) and BP
Very little new evidence on this topic has emerged since the previous BHS guidelines were published, and hence recommendations made in 1999 remain essentially unchanged.
Combined OCs tend to increase BP by an average of 5/3 mmHg. 271 In a small proportion of women (eg 1%), severe hypertension may be induced. 272 The mechanisms whereby BP increases occur are not established and the effect appears to be idiosyncratic in that no subgroups of women have been identified as being particularly susceptible. Furthermore, BP may rise rapidly many months or even years after first using a combined OC. Since the current use of combined OCs is not only associated with an increase in BP but also in risk of stroke and MI, 273 BP should be measured prior to OC use and 6 monthly thereafter.
Observational data suggest that progestogen-only contraceptive pills (POPs) do not, on average, increase BP, 274, 275 although virtually no trial evidence is available to confirm or refute this. However, POPs are currently recommended for women with hypertension induced by the combined OC, or women with hypertension wishing to use oral contraception.
While the combined OC is not absolutely contraindicated for women who are already hypertensive or even for those who develop hypertension on the combined OC, good BP control with antihypertensive medication is mandatory for such women who wish to remain on the combined OC. However, we recommend, pending further information, the use of the POP (with careful BP monitoring) for such women. It should be recognised that data on the impact of POPs on CVD risk are limited and that POPs are, in practice, less effective contraceptives than combined OCs. This is particularly important for younger women (o35 years), since they are more fertile, and therefore need safer contraception, and in whom the risks of cardiovascular events due to pregnancy outweigh likely risks due to use of the combined OC.
For women, particularly in those aged 435 years with other coexistent risk factors such as smoking and migraine (both of which are common in women of this age), we recommend that other nonhormonal forms of contraception should be sought. Greater protective effects against CVD are likely to accrue if the other risk factors-particularly smoking-could be effectively addressed.
Hormone replacement therapy (HRT) and BP
Observational data 276 and clinical trials evaluating various HRT formulations 277 suggest that, on average, the use of HRT does not cause BP to rise. On this basis, HRT is not contraindicated for women with hypertension, and women with hypertension should not be denied access to HRT as long as BP levels are effectively controlled to the latest optimal target levels (see earlier section). However, it is now clear that, contrary to the findings of extensive observational data, 278 several large randomised trials of commonly-used HRT formulations have established that 'opposed' HRT (containing oestrogen and progestogen) does not provide cardiovascular protection of any type in the context of primary prevention 279 or in those with established coronary disease. 280 Similarly, in the Women's Estrogen for Stroke trial (WEST) trial, 281 'unopposed' HRT (containing oestrogen only) did not prevent further stroke events in those with established cerebrovascular disease, and in the large Women's Health Initiative (WHI) trial of women with no prior cardiovascular diseases, which is still in progress, the unopposed HRT has also produced, at best, no reduction in major cardiovascular events.
Overall, best evidence of the impact of HRTwhether unopposed or opposed-is that cardiovascular events, coronary, venous thromboembolic and stroke, are increased by the use of those formulations evaluated hither to in randomised trials. 282 Equally surprising is that, overall, health-related quality of life was not improved by HRT use 283 and on balance a global risk index-incorporating fatal and nonfatal coronary disease, invasive breast cancer, stroke, pulmonary embolus, endometrial carcinoma, colonic cancer, hip fracture and other death was significantly worsened in association with the use of opposed HRT in the largest trial of HRT to date. 279 While it is possible that newer products such as the selective oestrogen receptor modulators or other formulations of opposed and unopposed oestrogen may not increase cardiovascular events or may even reduce them, current evidence dictates that HRT should not be prescribed to women with any expectation of reducing cardiovascular events. While the benefits of HRT for the treatment of severe menopausal symptoms are clear, users should be informed of the increased risks of cardiovascular and other serious disorders associated with their use.
Hypertension in pregnancy
Hypertension in pregnancy: This topic has been recently reviewed elsewhere. [284] [285] [286] [287] For convenience, a list of definitions of hypertension and the related terms in pregnancy are given in Table 5 . In pregnancy, DBP should be measured at the disappearance of sounds (phase V) and, unless phase V goes to zero, not at muffling (phase IV), as recommended in the past. 286, 287 Automated and ABPM devices have been validated for use in pregnancy. 288, 289 A note of caution is expressed about under-recording by automated devices in pre-eclampsia. 290 Hypertension occurs in 8-10% of pregnancies, and may be the first sign of impending preeclampsia, a potentially more serious condition of the second half of pregnancy and the puerperium. 290, 291 The Working Group of the American National Heart, Lung and Blood Institute classifies hypertension in pregnancy as: chronic hypertension, preeclampsia, pre-eclampsia superimposed on chronic hypertension and gestational hypertension. The latter becomes transient hypertension of pregnancy if pre-eclampsia is not present at the time of delivery and BP returns to normal by 12 weeks post-partum or chronic hypertension if the elevation persists. 286 Commenting on the difficulties in categorising hypertension in pregnancy and the lack of precision in the definition of pre-eclampsia, the authors 288 conclude that 'any definition that is used clinically should be as loose as practical for patient safety, whereas research definitions should be stringent'.
Care must be taken to distinguish between chronic hypertension and pre-eclampsia. Elevated BP before 20 weeks' gestation usually means that hypertension preceded pregnancy. This will commonly be 'essential', but clinical evaluation is needed, recognising that secondary hypertension may present for the first time in pregnancy. An apparent onset of hypertension after 20 weeks' gestation may reflect hypertension that was undetected prior to pregnancy, and disguised by the BP fall of early-mid pregnancy.
Meta-analysis of trials of antihypertensive drugs in pregnancy shows a reduction in the risk of progression to severe hypertension and fewer hospital admissions. 292 Firm evidence is not available on the optimal threshold for treatment. However, there is consensus for initiating treatment at BP levels exceeding 150-160 mmHg SBP or 100-110 mmHg DBP or in the presence of TOD 286 (for TOD definition, see Table 1 ). Many initiate treatment at lower levels, but there is concern that excessive BP reduction may limit foetal growth. 293 The principal objective of antihypertensive treatment is protection for the mother who, when BP levels are only modestly elevated, is at low absolute risk of adverse cardiovascular outcomes. There is little evidence that treatment reduces the risk of developing pre-eclampsia or improves foetal outcome, although effective control of severe hypertension may buy more gestational time before delivery becomes necessary. Women with essential hypertension are at increased risk of pre-eclampsia and intrauterine growth restriction (IUGR). Management should therefore include frequent BP checks, preferably once a week, urinalysis and sequential assessment of foetal growth. Hospital referral should be made if there is poorly controlled hypertension, new onset proteinuria or suspicion of IUGR.
Pre-eclampsia and eclampsia: Criteria for the diagnosis of pre-eclampsia include a rise in BP of 415 mmHg DBP or 430 mmHg SBP from early pregnancy, or DBP of 490 mmHg on two occasions 4 h apart or 4110 mmHg on one occasion and proteinuria (1 þ is a indication for referral and 4300 mg/24 h is the criterion for diagnosis). It is emphasised that 30% of eclamptic convulsions occur in the absence of either raised BP or proteinuria. Risk factors for pre-eclampsia include: first pregnancy, change of partner, previous preeclampsia, family history of pre-eclampsia, idiopathic hypertension, chronic renal disease, diabetes, systemic lupus erythematosus, multiple pregnancy and obesity. The increased risk of pre-eclampsia following change of partner 294 and the inverse association between risk and duration of sexual cohabitation before conception 295 implicate an immunological basis of the condition. 296, 297 In addition, immune reconstitution by antiretroviral treatment re-establishes a suppressed incidence of pre-eclampsia among women with human immunodeficiency virus to the rate expected in the normal population. 298 Women with pre-eclampsia generally have no symptoms and can only be detected by routine screening. When present, the most frequent symptoms are headache, visual disturbance (often 'flashing lights'), vomiting, epigastric pain and oedema. These symptoms in conjunction with raised BP require urgent referral and treatment. Women rarely present with a convulsion, but a first seizure in the second half of pregnancy with no other known cause is highly suggestive of eclampsia. The Magpie trial has demonstrated the efficacy of magnesium sulphate in halving the risk of mothers with preeclampsia progressing to eclampsia. 299 The role of low-dose aspirin in the prevention of pre-eclampsia has been controversial. Large trials have indicated no benefit, 300,301 but a recent systematic review has suggested a small protective effect. 302 Further trials of the potential protective effect of vitamins C and E, possibly via their antioxidant activity, are ongoing in women at risk of pre-eclampsia. 303, 304 Choice of antihypertensive therapy in pregnancy: Evidence underpinning the choice of antihypertensive therapy in pregnancy is inadequate to make firm recommendations. Methyldopa remains the antihypertensive drug of choice during pregnancy. 305, 306 CCBs (especially long-acting formulations of nifedipine) and the vasodilator hydralazine are commonly used as second-line drugs. Labetalol (alpha-and beta-blocker) is also widely used as a second-line agent, particularly for resistant hypertension in the third trimester. 307 Other beta-blockers are used less often, because of evidence that they particularly inhibit foetal growth. 308, 309 Meta-analysis of controlled trials of thiazide/thiazide-like diuretics has suggested a reduced incidence of preeclampsia. 310 In practice, thiazide/thiazide-like diuretics are used little for the management of hypertension, since on theoretical grounds they have the potential to further reduce the already decreased circulatory blood volume in women with pre-eclampsia. 311 However, there is no evidence that low-dose thiazide/thiazide-like diuretics in women with pre-existing hypertension are harmful and they may be continued through pregnancy. ACE inhibitors or ARBs should be avoided by women who wish to become pregnant and discontinued, ideally in the first trimster, if pregnancy occurs whilst taking these medications. This is necessary because in late pregnancy they may cause oligohydramnios, renal failure, hypotension and intrauterine death in the foetus. 312 It is frequently possible to withdraw antihypertensive medication altogether in the early stages while planning close follow-up. It is usual to switch from such agents back to the previous antihypertensive regimen after delivery.
The long-term prognostic implications of hypertensive disorders in pregnancy have become increasingly evident. It has previously been held that pre-eclampsia alone does not strongly predict future hypertension. 286, 313 However, in so far as a mother with underlying previously undiagnosed chronic hypertension is at increased risk of pre-eclampsia, this will translate to postnatal hypertension and the diagnosis of the problem that occurred during pregnancy may only be made with hindsight. Furthermore, three large cohort studies in Norway and Scotland indicate future hypertension and important increase in long-term CVD risk consequent to both gestational hypertension and preeclampsia. [314] [315] [316] The converse is clear-ie that women with normotensive births have a reduced probability of later hypertension. 286 Pragmatically, all women with hypertension disorders in pregnancy should have their BP checked regularly thereafter.
BP in ethnic minority groups
Most UK-based surveys show that black people of African or African-Caribbean origin have higher levels of BP and rates of hypertension than their Guidelines for management of hypertension B Williams et al white counterparts. [317] [318] [319] This is associated with higher rates of renal failure, 320 LVH 321 and stroke morbidity and mortality among the black population, 322 although CHD morbidity and mortality remain lower than in the white population. 322 In general, hypertension among the black population is particularly sensitive to dietary salt restriction, 323 and if drug therapy is required BP levels respond better to thiazide/thiazide-like diuretics or CCBs than to beta-blockers, 324 ACE inhibitors 8, 9 or angiotensin receptor blockers. 179 This presumably reflects the low renin status more frequently observed among the black population. 176 These differential BP responses to drug classes were reflected in significantly different rates of cardiovascular end points-particularly strokeassociated with use of these agents in the ALLHAT trial. 21 This was the first hypertension trial to have included sufficient numbers of black subjects to allow an evaluation of drug effects on morbidity and mortality in this population. Among the black (but not white) population in ALLHAT, stroke and coronary events were significantly higher among those randomised to the ACE inhibitor compared with those randomised to chlortalidone. 21 No differences in these end points were observed between those randomised to the thiazide/thiazide-like diuretic and those randomised to the dihydropyridine CCB amlodipine.
These data are supportive of the AB/CD algorithm proposed for elderly or black patients (see earlier section). The AASK trial 33 in African-American patients with renal impairment compared the ACE inhibitor ramipril with amlodipine, and the betablocker metoprolol. The amlodipine limb was stopped prematurely, because of a perceived worsening of renal failure in a subgroup of those randomised to amlodipine. The decision was controversial 325 and has been misinterpreted to mean that dihydropyridine CCBs are unsuitable for black patients with renal insufficiency. We recommend that an agent which blocks the renin-angiotensin system should always be part of any antihypertensive regimen for patients of this type, but that very strict BP lowering-which will often require a CCB-is pivotal to management.
American guidance on BP management for black patients is available in an extensive consensus statement outlining recommendations for the Management of High BP in African-Americans, which has recently been published. 326 Few new data relevant to hypertension management for British south Asians (from the Indian subcontinent) have been produced since the previous BHS guidelines, and hence recommendations relating to this group have not changed since 1999. It must be pointed out that essentially no morbidity/ mortality data from hypertension trials relating to this population are available. What limited data are available suggest that this population in the UK has higher mean BPs and hypertension prevalence than the white population. 317, 327 They also have high rates of type II diabetes, 328 tend to be insulin resistant, 328 and are at increased risk of stroke 322 and more particularly CHD 6 than whites in the UK. No robust data are available to suggest that south Asians respond differently to antihypertensive agents than do white Europeans, but the high prevalence of glucose intolerance or diabetes, central obesity and dyslipidaemia may influence drug choice (Table 2 ). These frequently coexistent conditions certainly require an assertive multifactorial approach to CVD risk management.
Implementation and audit
The challenges for the future
The objectives highlighted and prioritised in the previous guideline 3 are reiterated below and remain relevant:
to promote the primary prevention of hypertension and CVD by changes in the diet and lifestyle of the whole population; to increase the detection and treatment of undiagnosed hypertension by routine screening and increase awareness of hypertension among the public; to increase the proportion of patients on antihypertensive treatment who are controlled to optimal BP levels; to reduce the CVD risk of treated hypertensive patients by non pharmacological measures, and by appropriate use of aspirin and statin treatment; to increase the identification and treatment of patients with mild hypertension who are at high CVD risk, for example, elderly patients; those with ISH; people with diabetes; those with TOD or multiple risk factors; to promote the continuation of drug treatment, and adherence to treatment, by optimising the choice and use of drugs, minimising side effects, and increasing information and choice for patients.
Implementation
The successful implementation of these guidelines in the community depends on the combined and coordinated efforts of patients, clinicians and support staff who work within primary care and the wider community health care system. These guidelines come at an opportune time. Primary Care Trusts (PCTs) across the country are actively involved in service redesign. To implement this guideline effectively, new systems of health-care delivery will need to be developed in primary care. Multidisci-plinary teams will need to work in a systematic and structured way to advise, educate and support patients. This may involve the establishment of GPs with a Special Interest (GPSI) to lead clinical care in this area. This could result in a move away from rigid clinic-based care, towards a greater use of remote centres such as pharmacies, remote BP monitoring and diagnostic and treatment centres currently being developed, which would improve access and convenience for patients. Moreover, there is clearly a need for an extended role for nurse practitioners, pharmacists and other health-care professionals, to provide the foundation for the more widespread and effective detection, monitoring and treatment of BP and CVD risk.
The reduction of cardiovascular events in the population has been given a high priority by the Department of Health. This is illustrated by publication of the NSFs and by guidance issued by the National Institute for Clinical Excellence (NICE). Further support for the continued improvement in standards of care within primary and community care is provided by the new GMS contract for primary care. 329 These examples of emphasis and change in practice provide new opportunities to improve the clinical management of hypertension and CVD risk in the UK.
Supportive initiatives from the Department of Health
The NSFs were informed by the previous BHS guidelines 3 and those of the Joint British Societies. 76 These supportive initiatives have provided key drivers for improvements in care. Three NSFs are directly relevant to this guideline: the NSF for CHD, the NSF for older people and the NSF for diabetes.
National Service Framework for coronary heart disease (Department of Health-published March 2000) This document was drafted by patients, clinicians, managers and government to be the blue print for the modernisation of CHD services in England over the next 10 years. It supports the government's commitment to reduce the death rate from CHD and stroke and related diseases in people under 75 by at least 40% by 2010. The NSF for CHD sets 12 standards for improved prevention, diagnosis, treatment and rehabilitation of CHD and goals to secure fair access to high-quality services over the next 10 years. In Wales, a similar approach is being taken through 'Tackling CHD in Wales: Implementing Through Evidence'. 330 In Scotland, CHD and stroke have been combined and the equivalent document is CHD and stroke: Strategy for Scotland. 331 The NSF was intended to be a practical, evidencebased and flexible approach to tackling CHD. It (a) sets national standards, (b) defines service models for preventing and treating CHD and (c) establishes milestones and goals as performance indicators by which progress would be measured. To date, it has been successful in many of its aims.
The detection and treatment of hypertension was recognised to be important in reducing CVD. In both secondary prevention and high-risk primary prevention, advice and treatment was to be given to maintain BP below 140/85. A BP of less than 150 mmHg SBP and less than 90 mmHg DBP was given as the audit standard, consistent with the previous BHS guideline. 3 In contrast to these new BHS guidelines, the NSF defined 'high-risk primary prevention' as 'people without diagnosed CHD or other occlusive arterial disease but with a 10-year CHD risk 430%'. This equates to a 10-year CVD risk of 440%. This higher intervention threshold was set for valid pragmatic reasons. As new systems of care develop and mature, and when people at 'very high risk' have been successfully treated, the NSF suggests that primary-care physicians should intervene at lower levels of CVD risk.
The National Service Framework for older people (published by the Department of Health in March 2001) This NSF set out a programme of action and reform to address problems faced by older people. Various standards were set and the standard most relevant to these guidelines is Standard 5, which stated that 'The NHS will take action to prevent strokes, working in partnership with other agencies where appropriate. People who are thought to have had a stroke have access to diagnostic services, are treated appropriately by a specialist stroke service, and subsequently, with their carers, participate in a multidisciplinary programme of secondary prevention and rehabilitation'.
General practices were urged to build on their CHD registers and use them to identify those at risk of stroke. PCTs were given a target that by April 2004 every general practice, should identify and treat patients identified at being at risk of stroke; that is, those with high BP, atrial fibrillation or other risk factors as detailed in the NSF for CHD. Practices were advised to put in place models of care which included a systematic approach for (a) identifying those at high risk of stroke, (b) identifying and recording modifiable risk factors for people at high risk of stroke, (c) providing and documenting the delivery of appropriate advice for treatment, (d) offering a regular review to those at risk of stroke. Hypertension was recognised as being an important risk factor and lifestyle and pharmaceutical interventions are recommended to maintain BP below 140/85, consistent with current BHS guidance. 3 
National Service Framework for diabetes: standards published in December 2001
This programme was to be implemented over the 10 years from April 2003. It recognised that there was an interdependence between the diabetes NSF, the NSF for CHD and the stroke standard in the NSF for Older People. This is in addition to the planned NSF for renal services. Standard 4 states that 'all adults with diabetes shall receive high quality care throughout their lifetime, including support to optimise the control of their blood glucose, BP and other risk factors for developing the complications of diabetes'.
NICE guidance on essential hypertension These guidelines are in development and are expected to be published in early 2004. They differ from the present guideline in two important respects: (1) The NICE guidance will focus solely on the treatment of 'essential hypertension' in uncomplicated patients. It will not provide guidance on BP management in the many important sub-groups outlined in this report from the BHS. (2) Unlike BHS guidance, NICE guidance will not provide advice on when to use aspirin and statin therapy to reduce the total CVD risk burden of people with high BP.
The BHS believes that a return to single risk factor management, as suggested by the remit of the NICE guidance on BP management, is a retrogressive step. BP is a routine measurement advocated for all adults in the UK. When BP is found to be elevated, a patient is identified who is at increased CVD risk, not only as a consequence of their elevated BP, but also due to the common aggregation of other risk factors such as dyslipidaemia, impaired glucose tolerance and concomitant TOD (for TOD definition see Table 1 ), or cardiovascular complications. Optimal management of BP must therefore involve assessment of these risk factors and multifactorial intervention to reduce not only BP, but also CVD risk.
The New General Medical Services Contract for primary care (2003) This is seen by many as an important step forward in the development of British primary care services. When implemented throughout the UK, it will provide a major focus on quality of care and outcomes. The new quality framework is incenti- The percentage of patients with CHD, in whom the last blood pressure reading (measured in the last 15 months) is p150/90
70%
Stroke or transient ischaemic attacks Ongoing management
The percentage of patients with TIA or stroke who have a record of blood pressure in the notes in the preceding 15 months
90%
The percentage with a history of TIA or stroke whom the last blood pressure reading (measured in the last 15 months) is 150/90 or less
70%
Hypertension Records
The practice can produce a register of patients with established hypertension 9 Diagnosis and management
The percentage of patients with hypertension whose notes record smoking status at least once 10 90% The percentage of patients with hypertension who smoke, whose notes contain a record that smoking cessation advice has been offered at least once 10 90%
Ongoing management
The percentage of patients with hypertension in which there is a record of blood pressure in the past 9 months
90%
The percentage of patients with hypertension in whom the last blood pressure (measured in the last 9 months) is 150/90 or less 56 70%
Diabetes mellitus Ongoing management
The percentage of patients with diabetes who have a record of blood pressure in the past 15 months 3 90%
The percentage of patients with diabetes in whom the last blood pressure is 145/85 or less 17 55%
Records and information about patients The blood pressure of patients age 45 and over is recorded in the preceding five years for at least 55% of patients
-
The blood pressure of patients age 45 and over is recorded in the preceding five years for at least 75% of patients
CHD ¼ coronary heart disease; TIA ¼ transient ischaemic attack.
Guidelines for management of hypertension B Williams et al vised and will reward practices for delivering quality care to encourage even higher standards. The quality framework has four main 'domains'. The one that is likely to attract most interest from clinicians, and which provides the greatest financial reward, is that related to clinical standards. Cardiovascular disease is covered with standards related to CHD, stroke or TIA, hypertension and diabetes.
Each of the quality standards attracts points and points will result in financial rewards to practices which they can use to reward performance or develop services (see Table 6 ). Of the 550 Clinical Indicator points available, 158 relate directly to hypertension. There is a minimum threshold and, following achievement of this, funding increases in proportion to achievement until the maximum threshold is reached. As such, this new contract is likely to increase the focus on the detection and treatment of high BP and the quality of BP control.
Patient involvement
A vital aspect of the successful management and control of high BP is to obtain the participation and closer involvement of the individual affected.
Where appropriate, people with high BP should be involved in the decision as to whether they should take lifestyle action or commence drug therapy, and in particular decisions about which individual drugs they should take, possible side-effects and the likelihood that they may need to take at least two, or even three, different drugs in order to get their BP controlled. Many are willing and keen to measure their own BP, and with professional advice and new technologies, this can save visits to a doctor or nurse when treatment is being changed or in those who are well controlled. At the same time, involvement of the individual makes it much more likely that good control of BP will be achieved. The AB/CD algorithm defines treatment plan for people with high BP and copies of individualised treatment plans could be made available to patients treated for high BP. Appropriate information for individuals with high BP in the UK can be obtained from the Blood Pressure Association, a charitable organisation specifically set up to provide information and support to individuals with high BP. Three booklets are available which cover the importance of BP, healthy eating and medicines in detail and there are a range of further leaflets covering other aspects of BP. Individuals can obtain these leaflets directly from the Blood Pressure Association or via their healthcare professional and can join the Association as members. Contact details are listed in Appendix E.
Conclusion
The evidence presented in these new guidelines strongly support the recommendation that the detection and treatment of high BP and its associated CVD risk should be a key focus of health-care policy in the UK. The ongoing reorganisation of health-care provision in primary care and the emphasis on audit, quality of care and improvement in the systems of care, provide an excellent opportunity to implement these new BHS recommendations, and, in so doing, deliver much improved hypertension management and thereby reduce the burden of CVD.
